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Abstract Elevated glucose increases vascular reactivity by promoting L-type CaV1.2 channel
(LTCC) activity by protein kinase A (PKA). Yet, how glucose activates PKA is unknown. We
hypothesized that a Gs-coupled P2Y receptor is an upstream activator of PKA mediating LTCC
potentiation during diabetic hyperglycemia. Experiments in apyrase-treated cells suggested
involvement of a P2Y receptor underlying the glucose effects on LTTCs. Using human tissue,
expression for P2Y11, the only Gs-coupled P2Y receptor, was detected in nanometer proximity to
CaV1.2 and PKA. FRET-based experiments revealed that the selective P2Y11 agonist NF546 and
elevated glucose stimulate cAMP production resulting in enhanced PKA-dependent LTCC activity.
These changes were blocked by the selective P2Y11 inhibitor NF340. Comparable results were
observed in mouse tissue, suggesting that a P2Y11-like receptor is mediating the glucose response
in these cells. These findings established a key role for P2Y11 in regulating PKA-dependent LTCC
function and vascular reactivity during diabetic hyperglycemia.
DOI: https://doi.org/10.7554/eLife.42214.001
Introduction
Diabetes is a major risk factor contributing to cardiovascular complications, including hypertension,
increased risk of stroke, coronary disease, and organ failure (Whelton et al., 2018). These complica-
tions are often linked to the effects of elevated extracellular glucose (e.g. hyperglycemia - the hall-
mark metabolic abnormality in diabetes) on vascular function (Brown et al., 2010; Cooper et al.,
2001; Tousoulis et al., 2013). In addition to endothelium-dependent alterations (Lagaud et al.,
2001; Sena et al., 2013), endothelium-independent modifications, including enhanced contractility
of arterial myocytes, are emerging as critical contributing factors to these complications (Aron-
son, 2008; DeFronzo et al., 2013; Fleischhacker et al., 1999; Montero et al., 2013; Nieves-
Cintro´n et al., 2018). Consistent with this notion, we and others recently demonstrated augmented
vasoconstriction in response to acute and chronic elevations in extracellular glucose that were inde-
pendent of endothelial function (Fleischhacker et al., 1999; Jackson et al., 2016; Nystoriak et al.,
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2017). We linked these glucose-mediated effects on vascular reactivity to an increase in L-type
CaV1.2 channel (LTCC) activity in human and murine arterial myocytes (Navedo et al., 2010b;
Nystoriak et al., 2017). This is critical, as Ca2+ influx via LTCCs is the main Ca2+ entry pathway in
these cells and determines muscle contractility and arterial diameter (Knot and Nelson, 1998).
Unexpectedly, we found that glucose-mediated potentiation of LTCCs involves phosphorylation of
CaV1.2 at serine 1928 (Ser
1928) by protein kinase A (PKA) (Morotti et al., 2017; Navedo et al.,
2010b; Nystoriak et al., 2017). Yet, how glucose leads to PKA activation is unknown.
Elevations in cellular glucose have been shown to trigger autocrine release of nucleotides (e.g.
ATP, UTP) into the extracellular space of many cells, including arterial myocytes (Costa et al., 2009;
Hazama et al., 1998; Nilsson et al., 2006; Parodi et al., 2002). These extracellular nucleotides can
then act on G protein-coupled P2Y receptors to induce a plethora of cellular responses
(von Ku¨gelgen and Harden, 2011). Previous studies demonstrated that elevations in extracellular
glucose led to increases in intracellular Ca2+ ([Ca2+]i) in isolated arterial myocytes (Nilsson et al.,
2006). Indeed, this glucose-mediated response was associated with enhanced autocrine release of
nucleotides engaging P2Y receptors, but the contributing mechanisms as well as the identity of the
P2Y receptor involved are unclear.
Eight functionally diverse G protein-coupled P2Y receptors have been identified (von Ku¨gelgen
and Harden, 2011). Most of these P2Y receptors are coupled to Gq/i proteins. Conversely, P2Y11 is
the only P2Y receptor that is coupled to Gs (Communi et al., 1997; Kennedy, 2017;
Schuchardt et al., 2012; von Ku¨gelgen and Harden, 2011). Activation of this receptor could then
activate adenylyl cyclase (AC) and PKA to underlie the glucose-induced effects on LTCC activity, but
its role in arterial myocytes is unclear. P2Y11 receptors were first cloned from human tissue and sub-
sequently identified in other species (Kennedy, 2017; von Ku¨gelgen and Harden, 2011). Although
the P2Y11 gene has not been found at the expected position in the mouse genome, recent rodent
annotations related to this gene (e.g. XM_008766009.2 and XM_0130655917.2), as well as studies
defining a functional role based on pharmacological data obtained from rat and mouse tissue hinted
at the presence of at least a P2Y11-like receptor in mice (Kennedy, 2017). We, therefore, undertook
a comprehensive approach to investigate whether upstream engagement of this Gs-coupled P2Y
receptor is implicated in PKA activation leading to increased Ser1928 phosphorylation of vascular
CaV1.2 that results in potentiation of LTCC activity during diabetic hyperglycemia. Accordingly,
Western blot analysis, immunofluorescence confocal microscopy, Ground State Depletion (GSD)
super-resolution nanoscopy, FRET-based cAMP imaging and voltage-clamp electrophysiology con-
firmed functional expression of P2Y11 in human arterial myocytes. We found that elevated glucose
stimulates cAMP synthesis with the same magnitude as that observed upon application of the selec-
tive P2Y11 agonist NF546 or when both stimuli were given simultaneously, thus suggesting that glu-
cose and NF546 signaling proceed through the same pathway. Nanometer proximity was observed
between P2Y11 and PKA and P2Y11 and CaV1.2 at the sarcolemma of arterial myocytes, which facili-
tates a structural arrangement that may be essential for glucose effects on LTCC activity. Indeed,
the NF546/glucose-induced cAMP signal resulted in enhanced Ser1928 phosphorylation and LTCC
activity in human arterial myocytes, and these changes were prevented by the selective P2Y11 inhibi-
tor NF340. Intriguingly, comparable functional data were observed in mouse arterial myocytes, sug-
gesting that a P2Y11-like receptor could be mediating the glucose response in these cells that results
in vasoconstriction (Kennedy, 2017). Thus, our data in human and murine tissue indicate a key role
for a Gs-coupled P2Y receptor, which fits the distribution, pharmacological, and signaling profile of a
P2Y11 or P2Y11-like receptor, respectively, as an upstream player in the regulation of LTCCs and vas-
cular reactivity during diabetic hyperglycemia. These findings may have important clinical and thera-
peutic implications as they may point to P2Y11 as a potential target for treating diabetic vascular
complications.
Results
Glucose-induced extracellular nucleotide release mediates Ser1928
phosphorylation, increased LTCC activity and vasoconstriction
In our first series of experiments, we pressurized (60 mmHg) mouse cerebral arteries to develop sta-
ble and spontaneous tone (Supplementary file 1 and 2). When increasing extracellular glucose from
Prada et al. eLife 2019;8:e42214. DOI: https://doi.org/10.7554/eLife.42214 2 of 37
Research article Cell Biology Structural Biology and Molecular Biophysics
1 pA/pF
50 msec
-5
-4
-3
-2
-1
0
cu
rr
en
t d
en
sit
y 
(pA
/pF
)
10
5 min
0
10
20
30
40
%
 
a
rte
ria
l to
ne
10
10
10
apy
apy
10 mM D-glu
20 mM D-glu 
wt
 + apy
20 mM D-glu
0 Ca2+/nif
0 Ca2+/nif
20 mM D-glu
10 µM
pSer1928
CaV1.2
0.0
0.5
1.0
1.5
2.0
pS
er
19
28
/C
a
v1
.
2
re
la
tiv
e 
de
ns
ity
 (A
U)
apy
A
B
C
108 
µm
109 
µm
*
D-glu
(mM)
D-glu
(mM)
10
D-glu
(mM)
apy
10
apy
D-glu
(mM)
*
* *
20 20
20 20
20 20
20 20
250 
250 
kDa
Figure 1. Extracellular nucleotides promote vasoconstriction, CaV1.2 activity and Ser
1928 phosphorylation in
response to 20 mM D-glucose in murine arterial myocytes. (A) Representative diameter recordings and summary
arterial tone data from pressurized (60 mmHg) wt mouse cerebral arteries before and after application of 20 mM
Figure 1 continued on next page
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10 mM to 20 mM D-glucose, there was a significant constriction (Figure 1A and Supplementary file
1 and 2), which is consistent with previous reports by our group and others (Jackson et al., 2016;
Nystoriak et al., 2017). These extracellular D-glucose concentrations are used because they are
within the range of observed nonfasting glucose levels in nondiabetic and diabetic mouse models
(Lagaud et al., 2001; Moien-Afshari et al., 2008; Navedo et al., 2010b; Nieves-Cintro´n et al.,
2015; Nystoriak et al., 2014; Nystoriak et al., 2017). Considering that elevating glucose in the
external milieu may trigger autocrine release of nucleotides (Costa et al., 2009; Hazama et al.,
1998; Nilsson et al., 2006; Parodi et al., 2002), we investigated whether hydrolysis of extracellular
nucleotides would ablate glucose-mediated vasoconstriction. For these experiments, pressurized
arteries (60 mmHg) were pre-treated with the ectonucleotidase apyrase (0.32 U/mL) in a 10 mM
D-glucose solution for 10 min. Apyrase-treated arteries failed to constrict to 20 mM D-glucose
(Figure 1A and Supplementary file 2). Vasoconstriction in response to 60 mM potassium (K+) in
which the membrane potential closely follows the equilibrium potential for K+ (~ 20 mV) (Knot and
Nelson, 1998), was similar in control and apyrase-treated arteries (Figure 1—figure supplement 1A
and Supplementary file 1 and 2). These results suggest that differences in glucose-induced
Figure 1 continued
D-glucose in the absence (n = 6 arteries from six mice) and presence (n = 6 arteries from six mice) of apyrase (apy;
0.32 U/ml; *p<0.05, Wilcoxon matched pairs test; Figure 1—source data 1). (B) Characteristic IBa recordings from
the same cell and summary IBa data from wt mouse cerebral arterial myocytes evoked by step depolarizations from
 70 to +10 mV before and after application of 20 mM D-glucose in the absence (n = 11 cells from five mice) and
presence of apyrase (n = 9 cells from five mice) (*p<0.05, paired t test; Figure 1—source data 2). (C)
Representative immunoblot detection of phosphorylated Ser1928 (pSer1928) and total CaV1.2 from wt mouse
cerebral and mesenteric arteries after 10 min incubation with 10 mM or 20 mM D-glucose in the absence and
presence of apyrase (n = 10 arterial lysates per condition), and quantification of pSer1928 (AU = arbitrary units)
(*p<0.05, Kruskal-Wallis with Dunn’s multiple comparisons; Figure 1—source data 3).
DOI: https://doi.org/10.7554/eLife.42214.002
The following source data and figure supplements are available for figure 1:
Source data 1. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in
Figure 1A and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.010
Source data 2. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 1B.
DOI: https://doi.org/10.7554/eLife.42214.011
Source data 3. Excel spreadsheet containing the individual numeric values of pSer1928/CaV1.2 relative density ana-
lyzed in Figure 1C.
DOI: https://doi.org/10.7554/eLife.42214.012
Figure supplement 1. K+-induced arterial constriction in the absence and presence of apyrase, no changes in
arterial tone, IBa and pSer
1928 in response to 20 mM mannitol, and full-length blots corresponding to Figure 1C.
DOI: https://doi.org/10.7554/eLife.42214.003
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values of 60 mM K+-
induced % constriction analyzed in Figure 1—figure supplement 1A.
DOI: https://doi.org/10.7554/eLife.42214.004
Figure supplement 1—source data 2. Excel spreadsheet containing the individual numeric values of % arterial
tone analyzed in Figure 1—figure supplement 1B and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.005
Figure supplement 1—source data 3. Excel spreadsheet containing the individual numeric values of current den-
sity analyzed in Figure 1—figure supplement 1C.
DOI: https://doi.org/10.7554/eLife.42214.006
Figure supplement 1—source data 4. Excel spreadsheet containing the individual numeric values of pSer1928/a-
tubulin relative density analyzed in Figure 1—figure supplement 1E.
DOI: https://doi.org/10.7554/eLife.42214.007
Figure supplement 2. Enhanced IBa in response to elevated glucose is prevented by continuous bath perfusion.
DOI: https://doi.org/10.7554/eLife.42214.008
Figure supplement 2—source data 1. Excel spreadsheet containing the individual numeric values of current den-
sity analyzed in Figure 1—figure supplement 2B.
DOI: https://doi.org/10.7554/eLife.42214.009
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vasoconstriction were not due to an inability of apyrase-treated arteries to respond to 20 mM D-glu-
cose. Furthermore, the glucose-induced constriction was not attributed to changes in osmolarity as
treatment with equimolar concentrations of the nonpermeable mannitol (20 mM = 10 mM D-glu-
cose +10 mM mannitol) had no effect on vascular reactivity (Figure 1—figure supplement 1B and
Supplementary file 1 and 2).
LTCC activity is critical for vascular reactivity (Knot and Nelson, 1998), and its function is
enhanced in response to acute increases in glucose and in diabetes due to increased Ser1928 phos-
phorylation in the CaV1.2 carboxy terminal (Morotti et al., 2017; Navedo et al., 2010b;
Nystoriak et al., 2017). We, thus, examined whether nucleotide degradation with apyrase prevents
glucose-mediated increases in LTCC activity and Ser1928 phosphorylation. To assess this, we used
patch-clamp electrophysiology in the whole-cell perforated configuration with barium (Ba2+) as the
charge carrier, before and after application of nifedipine to determine the nifedipine-sensitive Ba2+
current (IBa) associated with LTCC activity in control and apyrase-treated cerebral arterial myocytes.
We found that 20 mM D-glucose significantly enhanced IBa in wild type (wt) control arterial myo-
cytes, but not in apyrase-treated cells (Figure 1B). The glucose effect on LTCC activity was not due
to changes in osmolarity as 20 mM mannitol had no impact on IBa (Figure 1—figure supplement
1C).
We next performed Western blot analysis with a specific phospho-antibody against Ser1928 at
CaV1.2 and a FP1 antibody for total CaV1.2 detection that have been extensively validated by our
group (Buonarati et al., 2017; Davare et al., 1999; Hall et al., 2013; Nystoriak et al., 2017;
Patriarchi et al., 2016). Indeed, we have previously shown that the immunoreactivity at 250 kDa of
CaV1.2 with the phospho-specific antibody for Ser
1928 (but not a phospho-specific antibody for
Ser1700) and FP1 are completely eliminated in tissue from S1928A knockin mice (Patriarchi et al.,
2016) and conditional CaV1.2 knockout mice (Buonarati et al., 2017), respectively. Data revealed
increased phosphorylation of this residue in response to 20 mM D-glucose in control arterial lysates
(Figure 1C and Figure 1—figure supplement 1D). However, this response was completely absent
in arterial lysates exposed to 20 mM mannitol, thus ruling out any osmolarity effects (Figure 1—fig-
ure supplement 1E). Moreover, glucose-induced Ser1928 phosphorylation was hindered in lysates
from apyrase-treated arteries (Figure 1C and Figure 1—figure supplement 1D). These results sug-
gest that elevated glucose increases Ser1928 phosphorylation to potentiate LTCC activity through an
autocrine mechanism involving secreted nucleotides.
To further test this possibility, LTCC activity was recorded in response to elevated glucose during
continuous perfusion or static bath conditions (as above). The rationale for these experiments was to
determine whether the wash out of nucleotides with flow can impact the glucose-induced potentia-
tion of LTCCs. We found statistically similar IBa in cells exposed to 10 mM and 20 mM D-glucose
under continuous bath perfusion (Figure 1—figure supplement 2). Conversely, IBa was significantly
elevated in arterial myocytes exposed to 20 mM D-glucose when the bath perfusion was stopped
(e.g. static bath conditions). These results suggest that secreted nucleotides could diffuse away
under continuous flow, whereas under static bath conditions, they could accumulate in or around the
area of release at the surface membrane of arterial myocytes to induce the optimal activation of the
signaling pathway underlying increased LTCC activity in response to elevations in extracellular
glucose.
P2Y11 receptors are in close proximity to CaV1.2 and PKAcat in arterial
myocytes
Extracellular nucleotides are well-known activators of G-coupled P2Y receptors (von Ku¨gelgen and
Harden, 2011). P2Y11 is a Gs-coupled P2Y receptor that could activate PKA (Communi et al., 1997;
Kennedy, 2017; Schuchardt et al., 2012; von Ku¨gelgen and Harden, 2011), and this could lead to
enhanced Ser1928 phosphorylation, LTCC activity, and vasoconstriction during diabetic hyperglyce-
mia. Using Western blot analysis, we first validated the P2Y11 antibody in tsA-201 cells, which endog-
enously express P2Y11 (Dreisig and Kornum, 2016), by over-expressing human GFP-tagged P2Y11
and by knocking down the endogenous and over-expressed receptor with specific P2Y11 antisense
oligodeoxynucleotides (ODNs) (Figure 2A and B). We subsequently detected an immunoreactive
band of the expected molecular weight for P2Y11 (~40 kDa) in lysates from freshly dissected human
adipose arteries (Figure 2C and Figure 2—figure supplement 1A). This band seems specific for
P2Y11 since treatment of human arteries with specific human P2Y11 antisense ODNs knocked
Prada et al. eLife 2019;8:e42214. DOI: https://doi.org/10.7554/eLife.42214 5 of 37
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Figure 2. P2Y11 protein and distribution in arterial myocytes. (A) Representative blot of immunoreactive bands of expected molecular weight for
endogenous P2Y11 (~40 kDa), overexpressed P2Y11-GFP (~70 kDa), and b-actin (~43 kDa) in untransfected, vehicle-treated (empty transfection) and
P2Y11-GFP transfected tsA-201 cells (n = 3 lysates per condition). Note that tsA-201 cells endogenously express P2Y11 (Dreisig and Kornum, 2016). (B)
Representative blot of immunoreactive bands of expected molecular weight for endogenous P2Y11 (~40 kDa), overexpressed P2Y11-GFP (~70 kDa), and
Figure 2 continued on next page
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down ~50% of the basal P2Y11 protein abundance (Figure 2—figure supplement 1B). Confocal
imaging and line profile analysis of P2Y11-associated fluorescence and the plasma membrane marker
wheat germ agglutinin (WGA) suggest a prominent distribution of the receptor on the surface mem-
brane of freshly dissociated human arterial myocytes (Figure 2D and E). This was not observed
when the antibody for P2Y11 was omitted from the preparation (Figure 2—figure supplement 1C).
These results suggest expression of P2Y11 in human arterial myocytes. We observed comparable
results in mouse arterial lysates and arterial myocytes, including detection and knock down with
P2Y11 ODNs of an immunoreactive band of the expected molecular weight for P2Y11 (Figure 2C and
Figure 2—figure supplement 1A, B and D). A band of ~110–120 kDa was observed in mouse arte-
rial lysates, perhaps reflecting the formation of heterodimers between the P2Y11 receptor itself or
other purinergic/G protein-coupled receptors, as previously reported (Barraga´n-Iglesias et al.,
2015; Barraga´n-Iglesias et al., 2014; Ecke et al., 2008; Nishimura et al., 2016). We also found
expected distribution of P2Y11-like-associated fluorescence at the surface membrane of mouse arte-
rial myocytes (Figure 2D and E), which was not observed when the primary antibody was omitted or
boiled (Figure 2—figure supplement 1C and E).
If P2Y11 is involved in PKA-mediated activation of LTCCs in response to elevated glucose, we
hypothesized that a subpopulation of these receptors should be localized in close proximity to
CaV1.2 and PKAcat. To test this possibility, we examined the spatial relationship of P2Y11 with CaV1.2
and PKAcat in freshly dissociated human arterial myocytes using GSD super-resolution nanoscopy in
the Total Internal Reflection Fluorescence (TIRF) configuration. This approach achieves a lateral reso-
lution of ~20 nm with selective illumination of the (sub)sarcolemmal region. Note that the FP1 anti-
body against CaV1.2 has been extensively validated by our group (Buonarati et al., 2017;
Hall et al., 2013; Nystoriak et al., 2017; Patriarchi et al., 2016). The PKAcat antibody was validated
in arterial myocytes by pre-absorption with a blocking peptide (Figure 3—figure supplement 1).
The GSD super-resolution localization maps (Figure 3A and B, bottom panels) for P2Y11, CaV1.2,
and PKAcat obtained from conventional TIRF images (Figure 3A and B, top panels) showed that
these proteins form clusters of various sizes (Figure 3C) and density (Figure 3D) at the sarcolemma
of human arterial myocytes. Whereas clusters were broadly expressed throughout the sarcolemma,
merged spatial maps of P2Y11 with CaV1.2 or PKAcat suggested a close association between a subset
of these proteins (Figure 3E and F). Indeed, histograms of the P2Y11-to-nearest CaV1.2 or PKAcat
distances revealed that the closest centroids for P2Y11-CaV1.2 and P2Y11- PKAcat were at 59 nm and
58 nm, respectively (Figure 3G and H). Similar results were observed using freshly dissociated
mouse cerebral arterial myocytes (Figure 3—figure supplement 2). Clusters of P2Y11, CaV1.2, or
PKAcat were never observed when primary antibodies were omitted from the human or mouse prep-
aration (Figure 3—figure supplement 3A and B). To determine whether the interaction between a
Figure 2 continued
b-actin (~43 kDa) in tsA-cells transfected with P2Y11-GFP as well as corresponding P2Y11 sense (SNS) or antisense (ANS) ODNs (64% reduction in
endogenous P2Y11 expression in cells treated with ANS; 62% reduction in P2Y11-GFP expression in P2Y11-GFP-transfected cells treated with ANS; n = 3
lysates per condition; Figure 2—source data 1). (C) Representative immunoblot detection of P2Y11 (~40 kDa) in lysates from human and wt mouse
arteries (n = 3 arterial lysates per sample). (D) Representative confocal images of P2Y11-associated fluorescence (green), wheat germ agglutinin (WGA,
red) and merged channels in human (n = 11 cells from three humans) and wt mouse (n = 14 cells from three mice) arterial myocytes. (E) Line profile of
the P2Y11- and WGA-associated fluorescence from the area highlighted by the dotted lines in the representative human and mouse arterial myocytes in
D.
DOI: https://doi.org/10.7554/eLife.42214.013
The following source data and figure supplements are available for figure 2:
Source data 1. Excel spreadsheet containing the individual numeric values of P2Y11/ b-actin relative density corresponding to values reported in legend
of Figure 2B.
DOI: https://doi.org/10.7554/eLife.42214.016
Figure supplement 1. Full-length blot for Figure 2C, knock down of P2Y11 in arterial lysates, P2Y11 immunoreactivity in isolated mouse arterial lysates,
negative controls for immunofluorescence experiments in Figure 2D and P2Y11 antibody control.
DOI: https://doi.org/10.7554/eLife.42214.014
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values of P2Y11/ b-actin relative density analyzed in Fig-
ure 2—figure supplement 1B.
DOI: https://doi.org/10.7554/eLife.42214.015
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Figure 3. Nanometer organization of P2Y11 with CaV1.2 and PKAcat in human arterial myocytes. Representative conventional TIRF images (top) and
corresponding GSD reconstruction maps (bottom) from human arterial myocytes labeled for (A) P2Y11 and CaV1.2 and (B) P2Y11 and PKAcat. Lower
panels display enhanced magnifications of areas shown in yellow boxes (scale bar, 400 nm). (C) Histograms of the area of P2Y11, CaV1.2 and PKAcat
clusters in isolated human arterial myocytes (1621 ± 29, 1209 ± 16 and 1322 ± 20 nm2, respectively; Figure 3—source data 1). (D) Bar plot of cluster
Figure 3 continued on next page
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subpopulation of P2Y11 with a pool of CaV1.2 and PKA in arterial myocytes is the result of specific
organization between two proteins, we compared the percentage of P2Y11 and CaV1.2/PKAcat over-
lap between experimental super-resolution localization maps and images containing randomized dis-
tribution of P2Y11, CaV1.2 and PKAcat. Randomized images for P2Y11-CaV1.2 and P2Y11-PKAcat were
generated based on data derived from the experimental super-resolution localization maps for these
pairs of proteins using the Coste’s randomization algorithm included in the JACoP plug-in in ImageJ
(Bolte and Cordelie`res, 2006). Our analysis found that the percentage of overlap between P2Y11-
CaV1.2 and P2Y11-PKAcat obtained from the experimental localization maps was significantly higher
than that observed for a simulated random distribution between P2Y11-CaV1.2 and P2Y11-PKAcat
(Figure 3I and Figure 3—figure supplement 3C). These results suggest an intimate association
between subpopulations of P2Y11-CaV1.2 and P2Y11-PKAcat.
We used the proximity ligation assay (PLA) as an additional analytical tool to examine the associa-
tion between P2Y11 and CaV1.2 or PKAcat. PLA fluorescence puncta are only observed if proteins of
interest are 40 nm or less apart (Fredriksson et al., 2002). We have extensively validated this
approach in previous studies (Nieves-Cintro´n et al., 2017; Nystoriak et al., 2017). Whereas PLA
signals were absent when at least one primary antibody was omitted (Figure 4—figure supplement
Figure 3 continued
density for P2Y11, CaV1.2 and PKAcat (38 ± 2, 29 ± 4, and 25 ± 3 clusters/mm
2, respectively; Figure 3—source data 2). Enlarged merged image (left) and
associated x-y fluorescence intensity profile (right) from area highlighted by the dotted lines of sites of close proximity between (E) P2Y11 (red) and
CaV1.2 (green) and (F) P2Y11 (red) and PKAcat (green) (scale bar, 200 nm). Histograms of the lowest intermolecular distance to P2Y11 centroids for (G)
CaV1.2 (n = 19,611 particles from 6 cells; Figure 3—source data 3) and (H) PKAcat (n = 22,425 particles from 6 cells; Figure 3—source data 4)
fluorescence particles. Data were fit with a sum of two Gaussian functions with depicted R2 and centroids. (I) Bar plot of % overlap of P2Y11 with CaV1.2
or PKAcat for experimental (CaV1.2: n = 36 segments from 12 cells; PKAcat: n = 22 segments from 11 cells) and randomized simulations images (CaV1.2:
n = 6 segments from 6 cells; PKAcat: n = 6 segments from 6 cells) (*p<0.05, unpaired t test with Welch’s correction; Figure 3—source data 5).
DOI: https://doi.org/10.7554/eLife.42214.017
The following source data and figure supplements are available for figure 3:
Source data 1. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for cluster area in Figure 3C.
DOI: https://doi.org/10.7554/eLife.42214.025
Source data 2. Excel spreadsheet containing the individual numeric values for cluster density in Figure 3D.
DOI: https://doi.org/10.7554/eLife.42214.026
Source data 3. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecular distance in Figure 3G.
DOI: https://doi.org/10.7554/eLife.42214.027
Source data 4. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecular distance in Figure 3H.
DOI: https://doi.org/10.7554/eLife.42214.028
Source data 5. Excel spreadsheet containing the individual numeric values for % of P2Y11 overlap in Figure 3I.
DOI: https://doi.org/10.7554/eLife.42214.029
Figure supplement 1. Validation for PKAcat primary antibody.
DOI: https://doi.org/10.7554/eLife.42214.018
Figure supplement 2. Nanometer organization of P2Y11, CaV1.2 and PKAcat in murine arterial myocytes.
DOI: https://doi.org/10.7554/eLife.42214.019
Figure supplement 2—source data 1. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for cluster area
in Figure 3—figure supplement 2C.
DOI: https://doi.org/10.7554/eLife.42214.020
Figure supplement 2—source data 2. Excel spreadsheet containing the individual numeric values for cluster density in Figure 3—figure supplement
2D.
DOI: https://doi.org/10.7554/eLife.42214.021
Figure supplement 2—source data 3. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecu-
lar distance in Figure 3—figure supplement 2G.
DOI: https://doi.org/10.7554/eLife.42214.022
Figure supplement 2—source data 4. Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecu-
lar distance in Figure 3—figure supplement 2H.
DOI: https://doi.org/10.7554/eLife.42214.023
Figure supplement 3. Negative controls for GSD images in human and murine arterial myocytes, and experimental and randomized reconstruction
maps.
DOI: https://doi.org/10.7554/eLife.42214.024
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Figure 4. P2Y11 associates with CaV1.2 and PKAcat in human and murine arterial myocytes. (A) Exemplary fluorescence PLA (red)/DAPI (blue) and
differential interference contrast (right) images of human arterial myocytes labeled for P2Y11 + CaV1.2 and P2Y11 + PKAcat. (B) Quantification of PLA
fluorescent puncta per cell area (puncta/mm2) for human arterial myocytes labeled for P2Y11 (n = 26 cells from three human samples), CaV1.2 (n = 20
cells from three humans), PKAcat (n = 17 cells from three humans), P2Y11 + CaV1.2 (n = 23 cells from three humans), and P2Y11 + PKAcat (n = 20 cells
Figure 4 continued on next page
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1), robust fluorescent puncta were detected in human (Figure 4A and B) and mouse (Figure 4C and
D) arterial myocytes co-labeled for P2Y11 and CaV1.2 or P2Y11 and PKAcat. Altogether, these results
suggest that human P2Y11 or mouse P2Y11-like receptors are located on the surface membrane of
arterial myocytes within nanometer proximity (~40 nm) of a subpopulation of CaV1.2 and PKAcat.
Increased sarcolemmal cAMP synthesis in arterial myocytes in response
to a P2Y11 agonist recapitulates glucose effects
P2Y11 can stimulate adenylyl cyclase (AC) activity to produce cAMP (Communi et al., 1997; Ken-
nedy, 2017; Schuchardt et al., 2012; von Ku¨gelgen and Harden, 2011). Thus, we first used a
membrane-targeted Epac1-camps-based FRET sensor (ICUE3-PM) (Allen et al., 2006; Liu et al.,
2011) expressed in tsA-201 cells to validate the P2Y11 pharmacology (Figure 5—figure supplement
1A) (Dreisig and Kornum, 2016). As expected, the highly selective P2Y11 agonist NF546 (500 nM)
(Meis et al., 2010) increased cAMP synthesis in these cells. This NF546-induced cAMP response
remained intact in cells pretreated with either selective P2Y1 (10 mM MRS2179) or P2Y6 (100 nM
MRS2578) inhibitors but was prevented in cells exposed to the selective P2Y11 inhibitor NF340 (10
mM; 500-fold more selective for P2Y11 than other P2Y receptors) (Meis et al., 2010).
We recapitulated the NF546-induced cAMP response and its ablation by pretreatment with
NF340 in primary, unpassaged human arterial myocytes expressing the ICUE3-PM sensor (Figure 5A
and B). Increasing D-glucose concentration from 5 mM to 15 mM, which are glucose concentrations
comparable to those observed in nondiabetic and diabetic patients respectively, induced a small yet
significant increase in cAMP synthesis in human cells (Figure 5A and B). The glucose effects are not
due to osmotic changes as equimolar concentrations of the non-permeable mannitol did not induce
any cAMP synthesis (Figure 5—figure supplement 1B). As expected, the synthesis of cAMP was fur-
ther amplified by the broad AC activator forskolin (1 mM) (Figure 5A) even in the presence of 20
mM mannitol (Figure 5—figure supplement 1B). Simultaneous application of 15 mM
D-glucose +NF546 resulted in cAMP synthesis of a similar magnitude to that induced by indepen-
dent treatments (Figure 5A and B). This suggests that the effects of elevated glucose and the
NF546 compound may be acting through a similar pathway that requires activation of P2Y11. Consis-
tent with this notion, application of NF546 by itself or 15 mM D-glucose +NF546 failed to induce
cAMP synthesis in cells pretreated with NF340 (Figure 5A and B). Yet forskolin, which bypasses
P2Y11, was still able to stimulate global cAMP production. Similar results were observed in murine
arterial myocytes expressing the ICUE3-PM sensor (Figure 5C and D and Figure 5—figure supple-
ment 1C). Intriguingly, cAMP synthesis in response to elevated glucose and the P2Y11 agonist
NF546 was significantly larger in human myocytes compared to mouse cells (glucose: 0.077 ± 0.003
in human vs 0.045 ± 0.002 in mouse; NF546: 0.083 ± 0.005 in human vs 0.045 ± 0.004 in mouse;
p<0.05). The reasons for this are currently unclear but may include intrinsic differences associated
with species (human vs mouse), blood vessels (human adipose arteries vs mouse aortae) and expres-
sion patterns of the biosensor in human vs mouse cells (Reddy et al., 2018), as well as variations in
protein expression and receptor/enzyme activity (e.g. P2Y11, AC and PDE expression/activity) in
human vs mouse arterial myocytes. Whether either or all of these factors contribute to distinctive
Figure 4 continued
from three humans) (*p<0.05, Kruskal-Wallis with Dunn’s multiple comparisons; Figure 4—source data 1). (C) Representative fluorescence PLA (red)/
DAPI (blue) and differential interference contrast (right) images of mouse arterial myocytes labeled for P2Y11 + CaV1.2 and P2Y11 + PKAcat. (D)
Quantification of PLA fluorescent puncta per mm2 cell area for mouse arterial myocytes labeled for P2Y11 (n = 44 cells from six mice), CaV1.2 (n = 15 cells
from six mice), PKAcat (n = 19 cells from six mice), P2Y11 + CaV1.2 (n = 25 cells from six mice), and P2Y11 + PKAcat (n = 29 cells from six mice) (*p<0.05,
Kruskal-Wallis with Dunn’s multiple comparisons; Figure 4—source data 2).
DOI: https://doi.org/10.7554/eLife.42214.030
The following source data and figure supplement are available for figure 4:
Source data 1. Excel spreadsheet containing the individual numeric values of puncta/mm2 graphs in Figure 4B.
DOI: https://doi.org/10.7554/eLife.42214.032
Source data 2. Excel spreadsheet containing the individual numeric values of puncta/mm2 graphs in Figure 4D.
DOI: https://doi.org/10.7554/eLife.42214.033
Figure supplement 1. Negative controls for PLA in human and murine arterial myocytes.
DOI: https://doi.org/10.7554/eLife.42214.031
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Figure 5. Glucose and the P2Y11 agonist NF546 increase sarcolemmal cAMP synthesis in arterial myocytes, and these effects are prevented by the
P2Y11 antagonist NF340. (A) Time course of YFP/CFP (donor/acceptor) FRET ratios (normalized to resting levels before treatment) in human arterial
myocytes expressing the ICUE3-PM biosensor in response to 15 mM D-glucose (black; n = 19 cells from two humans), 500 nM NF546 (green; n = 18
cells from two humans) and 15 mM D-glucose +500 nM NF546 (red; n = 14 cells from two humans) before and after application of broad adenylyl
Figure 5 continued on next page
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cAMP responses in human vs mouse arterial myocytes as well as their physiological implications
remain to be determined. Nevertheless, our findings suggest a role for human P2Y11 and mouse
P2Y11-like receptors in glucose-induced cAMP synthesis.
The P2Y11 inhibitor NF340 prevents glucose-induced Ser
1928
phosphorylation, LTCC activity and vasoconstriction
In our next series of experiments, we confirmed the glucose-induced increase in IBa detected in
mouse arterial myocytes (Figure 1B) using freshly dissociated human arterial myocytes in which
external glucose was elevated from 5 mM to 15 mM (Figure 6A and B). These results indicate that
elevations in extracellular glucose also stimulate LTCC activity in human arterial myocytes
(Nystoriak et al., 2017). The increase in IBa evoked by 15 mM D-glucose was prevented in human
cells pretreated with NF340 (Figure 6A and B). Glucose-induced potentiation of IBa was also pre-
vented in mouse arterial myocytes pretreated with NF340 (Figure 6C and D). However, inhibition of
P2Y6 receptors with MRS2578, which has been implicated in myogenic tone regulation and glucose-
induced NFAT activation in arterial myocytes (Brayden et al., 2013; Nilsson et al., 2006), failed to
stop the increase in IBa in response to 20 mM D-glucose (Figure 6C and D). Note that basal IBa were
similar in cells exposed to 10 mM D-glucose and 10 mM D-glucose +MRS2578, suggesting that inhi-
bition of P2Y6 did not alter basal LTCC activity (Figure 6C and D). Altogether, these results suggest
that P2Y6 receptors are not involved in glucose-induced potentiation of LTCC activity, and that these
glucose effects are prevented with a P2Y11 inhibitor.
Figure 5 continued
cyclase agonist forskolin (1 mM). In a set of experiments, cells were first pre-treated with the P2Y11 antagonist NF340 (10 mM) for at least 15–20 min
before treatment with 500 nM NF546 (orange; n = 15 cells from two humans) and 15 mM D-glucose +500 nM NF546 (blue; n = 13 cells from two
humans). Horizontal bars indicate treatment. Increases in cAMP production are represented by decreases in YFP/CFP ratio due to binding of cAMP to
the biosensor. (B) Bar plot of maximum FRET responses (YFP/CFP) for human arterial myocytes in response to the indicated treatment (*p<0.05,
Kruskal-Wallis with Dunn’s multiple comparisons; Figure 5—source data 1. Statistical differences were compared between 15 mM D-glucose vs NF546,
15 mM D-glucose vs 15 mM D-glucose +NF546, 15 mM D-glucose vs NF546 +NF340, 15 mM D-glucose vs 15 mM D-glucose +NF546+NF340, NF546 vs
NF546 +NF340, NF546 vs 15 mM D-glucose +NF546, NF546 vs 15 mM D-glucose +NF546+NF340, 15 mM D-glucose +NF546 vs 15 mM
D-glucose +NF546+NF340). (C) Time course of YFP/CFP (donor/acceptor) FRET ratios (normalized to resting levels before treatment) in mouse arterial
myocytes expressing the ICUE3-PM biosensor in response to 20 mM D-glucose (black; n = 83 cells from three mice), 500 nM NF546 (green; n = 13 cells
from three mice) and 20 mM D-glucose +500 nM NF546 (red; n = 13 cells from three mice). Horizontal bars indicate treatment. In a set of experiments,
cells were first pre-treated with the P2Y11 antagonist NF340 (10 mM) for at least 15–20 min before treatment with 500 nM NF546 (orange; n = 17 cells
from three mice) and 20 mM D-glucose +500 nM NF546 (blue; n = 18 cells from three mice). Increases in cAMP production are represented by
decreases in YFP/CFP ratio due to binding of cAMP to the biosensor. (D) Bar plot of maximum FRET responses (YFP/CFP) for mouse arterial myocytes
in response to the indicated treatment (*p<0.05, Kruskal-Wallis with Dunn’s multiple comparisons; Figure 5—source data 2. Statistical differences were
compared between all datasets).
DOI: https://doi.org/10.7554/eLife.42214.034
The following source data and figure supplements are available for figure 5:
Source data 1. Excel spreadsheet containing the individual numeric values for maximum FRET responses in Figure 5B.
DOI: https://doi.org/10.7554/eLife.42214.039
Source data 2. Excel spreadsheet containing the individual numeric values for maximum FRET responses in Figure 5D.
DOI: https://doi.org/10.7554/eLife.42214.040
Figure supplement 1. The P2Y11 agonist NF546 increases cAMP and this is blocked in the presence of the P2Y11 inhibitor NF340 but not with the P2Y1
inhibitor MSR2179 or P2Y6 inhibitor MRS2578 in tsA-201 cells, and no increases in cAMP in arterial myocytes with mannitol.
DOI: https://doi.org/10.7554/eLife.42214.035
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values for maximum FRET responses in Figure 5—figure
supplement 1A.
DOI: https://doi.org/10.7554/eLife.42214.036
Figure supplement 1—source data 2. Excel spreadsheet containing the individual numeric values for maximum FRET responses in Figure 5—figure
supplement 1B.
DOI: https://doi.org/10.7554/eLife.42214.037
Figure supplement 1—source data 3. Excel spreadsheet containing the individual numeric values for maximum FRET responses in Figure 5—figure
supplement 1C.
DOI: https://doi.org/10.7554/eLife.42214.038
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Figure 6. The P2Y11 inhibitor NF340 prevents glucose-induced elevations in Ser
1928 phosphorylation, LTCC activity, and vasoconstriction in human and
murine arterial myocytes. (A) Representative IBa recordings from the same cell and (B) summary current density data obtained from freshly dissociated
human arterial myocytes before and after increasing extracellular D-glucose from 5 mM to 15 mM in the absence (n = 12 cells from six humans) and
presence (n = 10 cells from five humans) of NF340 (10 mM) (*p<0.05, paired t test; Figure 6—source data 1). (C) Exemplary IBa traces from the same cell
Figure 6 continued on next page
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Since the P2Y11 inhibitor hindered the glucose effects on LTCC activity, we also explored whether
the NF340 compound interfered with the Ser1928 phosphorylation state of the channel and vascular
reactivity in response to hyperglycemia. As observed in mouse arteries (Figure 1C), we found that
elevating extracellular glucose significantly increased Ser1928 phosphorylation in human arterial
lysates (Figure 6E; Figure 6—figure supplement 1A). Yet, this glucose-mediated increase in Ser1928
phosphorylation was prevented if arterial lysates were pretreated with NF340, whereas phosphoryla-
tion still occurred if arterial lysates were pretreated with the P2Y6 inhibitor MRS2578 (Figure 6E and
F, and Figure 6—figure supplement 1A and B). Furthermore, vasoconstriction in response to ele-
vated glucose was blocked in pressurized (60 mmHg) mouse cerebral arteries exposed to NF340
(Figure 6G and H and Supplementary file 2) but not to MRS2578 (Figure 6I and J and
Supplementary file 2). Note that while arterial tone was similar in control and NF340-treated arter-
ies, it was reduced in arteries exposed to MRS2578 (Figure 6I and J), which is in line with recent
data showing that P2Y6 is a sensor of pressure-induced constriction (Brayden et al., 2013). Vasocon-
striction in response to 60 mM K+ was similar in control and NF340 as well as MRS2578-treated
arteries (Figure 6—figure supplement 1C and Supplementary file 1 and 2). We also evaluated a
potential role for P2Y1 receptors in stimulating PKA-mediated vasoconstriction as these receptors
have been suggested to crosstalk with P2Y11 to regulate their function in HEK cells and neurons
(del Puerto et al., 2012; King and Townsend-Nicholson, 2008). Data revealed that the glucose-
Figure 6 continued
and (D) amalgamated current density data recorded from mouse cerebral arterial myocytes treated with 10 mM NF340 (n = 8 cells from three mice) or
100 nM MRS2578 (n = 7 cells from five mice) before and after increasing extracellular D-glucose from 10 mM to 20 mM (*p<0.05, Kruskal-Wallis with
Dunn’s multiple comparisons; Figure 6—source data 2). Representative immunoreactive bands for phosphorylated Ser1928 (pSer1928) and total CaV1.2
and densitometry for pSer1928/CaV1.2 ratio in lysates from (E) human arteries exposed to 5 mM and 15 mM D-glucose in the absence and presence of
10 mM NF340 (n = 6 arterial lysates per condition; *p<0.05, Kruskal-Wallis with Dunn’s multiple comparisons; Figure 6—source data 3) and (F) mouse
cerebral and mesenteric arteries exposed to 10 mM or 20 mM D-glucose in the presence of 10 mM NF340 or 100 nM MRS2578 (n = 4 arterial lysates per
condition; *p<0.05 Kruskal-Wallis with Dunn’s multiple comparisons; Figure 6—source data 4). Representative diameter recordings and summary data
from pressurized (60 mmHg) mouse cerebral arteries exposed to (G–H) 10 mM NF340 (n = 4 arteries from four mice; Friedman with Dunn’s multiple
comparisons; Figure 6—source data 5) or (I–J) 100 nM MRS2578 (n = 7 arteries from seven mice; *p<0.05, Wilcoxon matched pair test; Figure 6—
source data 6) before and after application of 20 mM D-glucose.
DOI: https://doi.org/10.7554/eLife.42214.041
The following source data and figure supplements are available for figure 6:
Source data 1. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 6B.
DOI: https://doi.org/10.7554/eLife.42214.046
Source data 2. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 6D.
DOI: https://doi.org/10.7554/eLife.42214.047
Source data 3. Excel spreadsheet containing the individual numeric values of pSer1928/CaV1.2 relative density analyzed in Figure 6E.
DOI: https://doi.org/10.7554/eLife.42214.048
Source data 4. Excel spreadsheet containing the individual numeric values of pSer1928/CaV1.2 relative density analyzed in Figure 6F.
DOI: https://doi.org/10.7554/eLife.42214.049
Source data 5. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 6H and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.050
Source data 6. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 6J and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.051
Figure supplement 1. Full-length blots for Figure 6E and F, high K+induced constriction in arteries pretreated with NF340 and MRS2578
corresponding to data in Figure 6, and glucose-induced vasoconstriction is not prevented or inhibited by a selective P2Y1 antagonist.
DOI: https://doi.org/10.7554/eLife.42214.042
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values of 60 mM K+-induced % constriction analyzed in Fig-
ure 6—figure supplement 1C.
DOI: https://doi.org/10.7554/eLife.42214.043
Figure supplement 1—source data 2. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 6—figure sup-
plement 1D and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.044
Figure supplement 1—source data 3. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 6—figure sup-
plement 1E and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.045
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induced vasoconstriction was not altered by adding the selective P2Y1 inhibitor MRS2179 (10 mM)
either before or after 20 mM D-glucose stimulation (Figure 6—figure supplement 1D and E and
Supplementary file 1 and 2). These results suggest that the P2Y1 receptor is not involved in glu-
cose-mediated vasoconstriction. Together, these data demonstrate the effectiveness of a P2Y11
inhibitor in blocking the remodeling of Ser1928 phosphorylation and LTCC activity that mediates
vasoconstriction in response to elevated glucose.
The P2Y11 agonist NF546 stimulates Ser
1928 phosphorylation, PKA-
dependent LTCC activity and vasoconstriction
We next investigated whether a selective P2Y11 agonist could recapitulate the glucose-mediated
Ser1928 phosphorylation and PKA-dependent LTCC activity. Using freshly dissociated human arterial
myocytes, we found that IBa was significantly increased by application of NF546 (Figure 7A). This
P2Y11 agonist also increased IBa at multiple membrane potentials in mouse arterial myocytes with no
change in the current-voltage (I-V) relationship (Vmax = 14.9 ± 2.0 mV for 10 mM D-glucose and
Vmax = 10.9 ± 1.1 mV for NF546; p=0.1085, extra sum-of-squares F test) (Figure 7B). The NF546-
mediated increase in IBa was similar in magnitude to that induced by elevated glucose (Figure 7—
figure supplement 1A). Similar IBa potentiation was also observed after application of the non-
hydrolyzed ATP analog and potent P2Y11 agonist ATPgS (1 mM; Figure 7—figure supplement 1B)
(von Ku¨gelgen and Harden, 2011). Note that ATPgS stimulates P2Y11 activity with EC50 that ranges
from 31 nM to 23 mM, depending on readout, cell type and species used, but it is still a more potent
activator than ATP itself (Communi et al., 1999; Haas et al., 2014; Kennedy, 2017; Meis et al.,
2010; Qi et al., 2001; Schuchardt et al., 2012; von Ku¨gelgen and Harden, 2011). We further cor-
related the potentiation in IBa by NF546 to an elevation of Ser
1928 phosphorylation in freshly dis-
sected human and mouse arterial lysates (Figure 7C and Figure 7—figure supplement 1C). Since
PKA is essential for glucose-mediated remodeling of IBa in arterial myocytes and can be activated
downstream of P2Y11 (Navedo et al., 2010b; Nystoriak et al., 2017), we also examined its involve-
ment in NF546-mediated potentiation of LTCC activity in arterial myocytes. Consistent with a key
role for PKA, NF546 failed to upregulate IBa in arterial myocytes incubated with the PKA inhibitors
PKI (100 nM) or rpcAMP (10 mM) (Figure 7D).
Having established that application of the P2Y11 agonist NF546 influences Ser
1928 phosphoryla-
tion state as well as LTCC activity, we investigated whether it could also modulate arterial tone.
Accordingly, pressurized (60 mmHg) arteries that developed stable arterial tone and responded to
60 mM K+ (Figure 7—figure supplement 1D and Supplementary file 1 and 2) showed significant
constriction upon NF546 application (Figure 7E). Interestingly, NF546 did not induce further con-
striction in wt arteries previously exposed to 20 mM D-glucose (Figure 7F). Indeed, arterial tone was
similar in arteries treated with 20 mM D-glucose or 20 mM D-glucose +NF546 (Supplementary file
1 and 2). Confirming a critical role for Ser1928, arteries from a S1928A knockin mouse in which phos-
phorylation of this CaV1.2 amino acid is prevented (Lemke et al., 2008; Nystoriak et al., 2017;
Qian et al., 2017), failed to constrict to NF546 (Figure 7F and Supplementary file 1 and
2). Response of S1928A arteries to 60 mM K+ was similar to those observed for wt arteries (Fig-
ure 7—figure supplement 1D and Supplementary file 1 and 2). These results suggest that a P2Y11
agonist can induce Ser1928 phosphorylation, PKA-dependent LTCC potentiation and vasoconstric-
tion, thus recapitulating glucose effects (Navedo et al., 2010b; Nystoriak et al., 2017), and provid-
ing further evidence of the involvement of human P2Y11 and mouse P2Y11-like receptors in these
alterations.
Increased Ser1928 phosphorylation and LTCC activity during chronic
diabetic hyperglycemia are prevented by a P2Y11 inhibitor
To explore whether a P2Y11 inhibitor could prevent changes in Ser
1928 phosphorylation and LTCC
activity during chronic diabetic hyperglycemia, we exposed isolated arteries for 48 hr to 10 mM
D-glucose, 20 mM mannitol, 20 mM D-glucose or 20 mM D-glucose +NF340. This organ culture
method prevents arterial myocyte phenotypic changes associated with prolonged culturing condi-
tions. Furthermore, the exposure time is sufficient to induce many of the vascular remodeling phe-
nomena associated with elevated glucose in arterial myocytes, including increased LTCC activity,
decreased K+ channel activity and downstream activation of Ca2+-dependent transcription factors
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Figure 7. The P2Y11 agonist NF546 increases Ser
1928 phosphorylation, LTCC activity, and induces vasoconstriction. (A) Representative IBa recordings
from the same cell (top) and summary IBa data (bottom) from freshly dissociated human arterial myocytes in response to step depolarizations from  70
to +10 mV before and after application of 500 nM NF546 (n = 11 cells from five humans; *p<0.05, paired t test; Figure 7—source data 1). (B)
Representative IBa recordings from the same cell (left) triggered by step depolarization from  70 mV to voltages ranging from  60 to +60 mV before
Figure 7 continued on next page
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(Navedo et al., 2010b; Nieves-Cintro´n et al., 2015; Nilsson et al., 2006; Nystoriak et al., 2014;
Nystoriak et al., 2017). LTCC function was assessed by measuring single-channel activity using the
cell-attached configuration from dissociated arterial myocytes under each experimental condition
described above. We found that wt cells isolated from the 20 mM D-glucose but not the 20 mM
mannitol treated group had significantly enhanced LTCC open probability (nPo) compared to those
in the 10 mM D-glucose group (Figure 8A and B). This increase in LTCC activity during diabetic
hyperglycemia, however, was prevented in arterial myocytes from arteries treated in the presence of
the P2Y11 inhibitor NF340. Ser
1928 phosphorylation was significantly elevated in arteries chronically
exposed to 20 mM D-glucose, but this effect was completely abolished in the presence of NF340
(Figure 8C and Figure 8—figure supplement 1A). Consistent with a key role for Ser1928 phosphory-
lation in potentiation of LTCC activity in response to chronic elevations in glucose, LTCC nPo was
similar in arterial myocytes from S1928A arteries incubated for 48 hr in 10 mM or 20 mM D-glucose
(Figure 8—figure supplement 1B). These results suggest that treatment with a P2Y11 inhibitor can
Figure 7 continued
and after application of 500 nM NF546 in mouse cerebral arterial myocytes and corresponding IBa-voltage relationship (right) (n = 8 cells from five mice)
(*p<0.05, paired t test; Figure 7—source data 2). (C) Exemplary immunoblot detection of phosphorylated Ser1928 (pSer1928) and total CaV1.2 from
human (left) and mouse cerebral and mesenteric arteries (right) incubated with 500 nM NF546 and respective densitometry quantification of pSer1928/
CaV1.2 ratio (n = 6 arterial lysates per condition for humans; n = 6 arterial lysates per condition for mice) (*p<0.05, Wilcoxon matched pairs test;
Figure 7—source data 3). (D) Representative IBa recordings from the same cell (top) and summary IBa data (bottom) from mouse arterial myocytes
evoked by step depolarizations from  70 to +10 mV before and after application of 500 nM NF546 in the absence (n = 9 cells, four mice) and presence
of 100 nM PKI (n = 9 cells, five mice) or 10 mM rpcAMP (n = 9 cells, four mice) (*p<0.05, paired t test; Figure 7—source data 4). (E) Representative
diameter recording and summary arterial tone data from pressurized (60 mmHg) mouse cerebral arteries exposed to 500 nM NF546 (n = 6 arteries, six
mice) (*p<0.05, Wilcoxon matched pairs test; Figure 7—source data 5). (F) Representative diameter recordings and summary arterial tone data from
pressurized (60 mmHg) wt mouse cerebral arteries exposed to 20 mM D-glucose before and after application of 500 nM NF546 (n = 6 arteries, six mice,
left; *p<0.05, Friedman with Dunn’s multiple comparisons; Figure 7—source data 6) and S9128A mouse cerebral arteries after NF546 application
(n = 4 from three mice, right; Figure 7—source data 6).
DOI: https://doi.org/10.7554/eLife.42214.052
The following source data and figure supplements are available for figure 7:
Source data 1. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 7A.
DOI: https://doi.org/10.7554/eLife.42214.057
Source data 2. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 7B.
DOI: https://doi.org/10.7554/eLife.42214.058
Source data 3. Excel spreadsheet containing the individual numeric values of pSer1928/CaV1.2 relative density analyzed in Figure 7C.
DOI: https://doi.org/10.7554/eLife.42214.059
Source data 4. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 7D.
DOI: https://doi.org/10.7554/eLife.42214.060
Source data 5. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 7E and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.061
Source data 6. Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in Figure 7F and corresponding raw diameters.
DOI: https://doi.org/10.7554/eLife.42214.062
Figure supplement 1. D-glucose and NF546 elicit changes in IBa of similar magnitude in mouse arterial myocytes, ATPgS increases IBa in arterial
myocytes, full-length blots corresponding to data in Figure 7C, and high K+-induced constriction in wt and S1928A arteries treated with NF546
corresponding to data in Figure 7.
DOI: https://doi.org/10.7554/eLife.42214.053
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values of change in current density analyzed in Figure 7—
figure supplement 1A.
DOI: https://doi.org/10.7554/eLife.42214.054
Figure supplement 1—source data 2. Excel spreadsheet containing the individual numeric values of current density analyzed in Figure 7—figure sup-
plement 1B.
DOI: https://doi.org/10.7554/eLife.42214.055
Figure supplement 1—source data 3. Excel spreadsheet containing the individual numeric values of 60 mM K+-induced % constriction analyzed in Fig-
ure 7—figure supplement 1D.
DOI: https://doi.org/10.7554/eLife.42214.056
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Figure 8. Augmented LTCC activity and Ser1928 phosphorylation in response to chronic extracellular glucose elevations are prevented in the presence
of the P2Y11 antagonist NF340. (A) Representative single LTCC recordings obtained during a 2 s step depolarization from  80 to  30 mV and (B) bar
plot of LTCC nPo in arterial myocytes isolated from mouse cerebral arteries incubated for 48 hr in 10 mM D-glucose (n = 10 cells from three mice), 20
mM mannitol (n = 13 cells from four mice), 20 mM D-glucose (n = 10 cells from four mice) and 20 mM D-glucose +10 mM NF340 (n = 10 cells from four
Figure 8 continued on next page
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avert PKA-mediated Ser1928 phosphorylation and stimulated LTCC activity during diabetic
hyperglycemia.
Discussion
Increased arterial myocyte contractility and vasoconstriction in response to elevated extracellular
glucose contribute to vascular complications in diabetes (Cooper et al., 2001; Fleischhacker et al.,
1999; Jackson et al., 2016; Montero et al., 2013; Nieves-Cintro´n et al., 2015; Nystoriak et al.,
2017). This endothelium-independent component is attributed, at least in part, to glucose-induced
decreases in K+ channel expression and activity (Jackson et al., 2016; Nieves-Cintro´n et al., 2015;
Nieves-Cintro´n et al., 2017; Nieves-Cintro´n et al., 2018; Nystoriak et al., 2014; Straub et al.,
2009), transcriptional remodeling through NFATc3 signaling (Nieves-Cintro´n et al., 2015; Nieves-
Cintro´n et al., 2018; Nilsson et al., 2006; Nystoriak et al., 2014), and alterations in PKC/Rho
kinase signaling (Abd-Elrahman et al., 2015; Hien et al., 2016; Kizub et al., 2010). Our group has
additionally established, in human and mouse arterial tissue, PKA-mediated potentiation of LTCC
activity via increased phosphorylation of the pore-forming CaV1.2 subunit at Ser
1928 as a key event
that contributes to vascular complications during diabetic hyperglycemia (Morotti et al., 2017;
Navedo et al., 2010b; Nystoriak et al., 2017). The classic molecular machinery stimulating PKA
activity implicates activation of upstream effector enzymes (e.g. AC) and G protein-coupled recep-
tors (GPCR). In the present study, using native human arteries and arterial myocytes, we identified a
Gs-coupled P2Y receptor with the molecular, pharmacological, and signaling properties of P2Y11 as
the GPCR underlying the glucose triggering cascade that results in PKA-dependent potentiation of
LTCCs (Figure 8D). Indeed, P2Y11 is known to associate with ACs to stimulate cAMP/PKA signaling
(Communi et al., 1997; Puce´at et al., 1998). Similar results were observed in mouse arteries and
arterial myocytes, indicating that a P2Y11-like receptor could be mediating the glucose response in
these cells. The implications of these observations are profound, as they may shed light on unique
mechanisms of diabetic vascular complications.
Elevations in extracellular glucose have been shown to promote autocrine release of nucleotides
in a number of cells, including arterial myocytes (Costa et al., 2009; Hazama et al., 1998;
Nilsson et al., 2006; Parodi et al., 2002). This glucose-induced release of nucleotides has been
associated with increased global [Ca2+]i in arterial myocytes, but the mechanisms and functional
implications were not clearly established (Nilsson et al., 2006). This prompted us to examine
whether extracellular nucleotides could be mediating glucose effects on LTCC activity and vascular
Figure 8 continued
mice). Channel openings (o) are represented by downward deflections from baseline (c) (*p<0.05, one-way ANOVA with Tukey post hoc test;
Figure 8—source data 1). (C) Representative immunoblot detection of phosphorylated Ser1928 (pSer1928) and total CaV1.2 from mouse cerebral and
mesenteric arteries incubated for 48 hr in 10 mM D-glucose, 20 mM D-glucose and 20 mM D-glucose +10 mM NF340 and densitometry quantification of
pSer1928/CaV1.2 ratio (n = 7 arterial lysates per condition) (*p<0.05, Kruskal-Wallis with Dunn’s multiple comparisons; Figure 8—source data 2). (D)
Proposed model for the role of P2Y11 in PKA-dependent stimulation of LTCC activity and vasoconstriction during diabetic hyperglycemia
(NUC = nucleotides).
DOI: https://doi.org/10.7554/eLife.42214.063
The following source data and figure supplements are available for figure 8:
Source data 1. Excel spreadsheet containing the individual numeric values of LTCC nPo analyzed in Figure 8B.
DOI: https://doi.org/10.7554/eLife.42214.066
Source data 2. Excel spreadsheet containing the individual numeric values of pSer1928/CaV1.2 relative density analyzed in Figure 8C.
DOI: https://doi.org/10.7554/eLife.42214.067
Figure supplement 1. Full-length blots corresponding to data in Figure 8C and unchanged LTCC nPo in response to chronic elevations in extracellular
glucose in S1928A arterial myocytes.
DOI: https://doi.org/10.7554/eLife.42214.064
Figure supplement 1—source data 1. Excel spreadsheet containing the individual numeric values of LTCC nPo analyzed in Figure 8—figure supple-
ment 1B.
DOI: https://doi.org/10.7554/eLife.42214.065
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reactivity. Our first major finding was that hydrolysis of extracellular nucleotides by the ectonucleoti-
dase apyrase prevented the increases in Ser1928 phosphorylation, LTCC activity and vasoconstriction
in response to elevations in extracellular glucose (Figure 1). Outcomes from LTCC recordings under
continuous flow or static bath conditions (Figure 1—figure supplement 2) further support the
involvement of extracellular nucleotide signaling in mediating the glucose effects. Given the well-
established function of extracellular nucleotides in activating P2Y receptors (see (von Ku¨gelgen and
Harden, 2011)), our studies also pointed to the potential contribution of at least one of the eight
known P2Y receptors in this process. In line with this concept, our multidisciplinary approach using
human tissue suggested involvement of a P2Y receptor fitting the profile for the P2Y11 subtype.
Intriguingly, similar results were observed using mouse tissue/cells, suggesting a role for a P2Y11-like
receptor. To date, this is the only Gs-coupled P2Y, which could activate AC, leading to increased
cAMP synthesis and thereby PKA activation. Considering the essential actions of PKA on LTCC activ-
ity and vasoconstriction in response to elevated glucose (Morotti et al., 2017; Navedo et al.,
2010b; Nystoriak et al., 2017), we submit that such changes may proceed through activation of
this purinergic signaling pathway.
Few studies have examined the role of P2Y11 in the cardiovascular system. Current knowledge
suggests that this receptor is associated with positive inotropic effects of ATP on cardiomyocytes
and its activity seems to be impaired during cardiomyopathy (Balogh et al., 2005). Moreover, a
polymorphism (Ala-87-Thr) in P2Y11 has been linked to increased risk of acute myocardial infarction
and C-reactive protein blood levels (Amisten et al., 2007). These results indicate a role for P2Y11 in
cardiac (dys)function. However, the functional significance of P2Y11 in the vasculature, and particu-
larly in arterial myocytes, is virtually unknown. In the present study, Western blot analysis detected
an immunoreactive band of the expected molecular weight for P2Y11 (e.g. ~40 ± 10 kDa) in human
arterial lysates (Figure 2C). We confirmed robust distribution of the receptor at the expected plasma
membrane location in isolated human arterial myocytes (Figure 2D). In line with the expected func-
tion for this GPCR, we corroborated localized subplasmalemmal cAMP synthesis upon receptor stim-
ulation with a highly selective P2Y11 agonist (NF546 (Meis et al., 2010); Figure 5). Notably, 20 mM
D-glucose triggered cAMP synthesis of the same magnitude as the NF546 compound, and simulta-
neous application of NF546 and 20 mM D-glucose did not have any additional effect when com-
pared with individual treatment exposure, suggesting that both stimuli proceed through the same
signaling pathway. In support of this possibility, the specific P2Y11 antagonist NF340 (Meis et al.,
2010) blocked the NF546 and NF546 + 20 mM D-glucose effects on cAMP synthesis (Figure 5). The
P2Y11 antagonist also prevented increased Ser
1928 phosphorylation and LTCC activity in response to
acute elevations in extracellular glucose (Figure 6), while the P2Y11 agonist NF546 recapitulated all
the glucose-induced, PKA-dependent effects (Figure 7). Moreover, the NF340 compound hampered
glucose-induced changes in Ser1928 phosphorylation levels and LTCC activity during chronic hyper-
glycemic conditions resembling those observed during diabetes (Figure 8). Altogether, these results
revealed a role for human P2Y11 or mouse P2Y11-like receptor in arterial myocytes, particularly dur-
ing glucose signaling, and suggest that this GPCR may be involved in the initiation and/or progres-
sion of arterial myocyte dysfunction leading to vascular complications during diabetic
hyperglycemia. Our results may also have profound clinical implications as they add to a growing
body of evidence implicating a role for altered P2Y11 function in a number of pathological conditions
(Nishimura et al., 2017), which could make them a potential therapeutic target.
Our findings indicating that elevated extracellular glucose triggers PKA-dependent potentia-
tion of LTCC activity to induce vasoconstriction were unexpected, as PKA activity has been tra-
ditionally associated with vasodilation due, in part, to increased K+ channel activity. A
reasonable prediction was that glucose could influence LTCCs via a cAMP/PKA signaling path-
way that is distinct from that governing K+ channels as occurs upon b adrenergic stimulation
(Moore et al., 2014). Such separation in cAMP would require precise subsarcolemmal compart-
mentalization of key proteins and signaling molecules (including GPCR, signaling enzyme, second
messenger, effector protein and substrate). In the case of PKA-dependent effects on LTCC func-
tion in response to elevated glucose, this separation would include seclusion of a Gs-coupled
receptor, AC, PKA and CaV1.2. Indeed, Tajada et al recently showed that optimal ion channel
regulation by effector proteins is constrained by their nanometer distance between each other
(Tajada et al., 2017). In support of this possibility, our recent work revealed nanometer proxim-
ity of a subpopulation of CaV1.2 (~10% of CaV1.2 clusters) to pools of PKA (Nystoriak et al.,
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2017). Here, we found a close association (40–90 nm) between pools of P2Y11 and CaV1.2 as
well as P2Y11 and PKA (Figure 3). Moreover, given the cAMP biosensor data demonstrating
that both glucose and the P2Y11 agonist NF546 induce localized subsarcolemmal cAMP synthesis
(Figure 5), it is also likely that P2Y11 may be in close proximity to a specific AC isoform in arte-
rial myocytes - the identity of which remains to be established. Nevertheless, this implicates the
formation of a distinctive nanomolecular domain likely containing P2Y11, AC, PKA and CaV1.2 in
arterial myocytes (Figure 8D), although its confirmation is beyond the scope of this study. This
nanodomain may ensure the necessary signaling compartmentalization required for PKA-medi-
ated effects on LTCC activity and vascular reactivity in response to elevated glucose.
The spatial organization of the P2Y11/AC/PKA/CaV1.2 nanodomain could be facilitated by scaffold
proteins, such as A kinase anchoring proteins (AKAPs). These AKAPs fine tune signal transduction by
localizing GPCRs, signaling enzymes and effector proteins in close proximity to their substrates
(Johnstone et al., 2018; Langeberg and Scott, 2015). The A kinase anchoring protein 150
(AKAP150; murine ortholog of human AKAP79) is of particular interest as it has been shown to inter-
act with AC, PKA and CaV1.2 (Bauman et al., 2006; Efendiev et al., 2010; Gao et al., 1997;
Murphy et al., 2014; Navedo et al., 2008; Nystoriak et al., 2017; Zhang et al., 2013). Intriguingly,
although AKAP79/150 can associate with multiple GPCRs (Fraser et al., 2000; Zhang et al., 2011),
no report to date has linked it to any purinergic receptor. Localization of P2Y11 within the same
AKAP79/150-driven complex may be critical as this scaffold protein is necessary for increased L-type
Ca2+ channel activity in response to elevated glucose (Nystoriak et al., 2017). Two possibilities that
do not exclude a fundamental role for AKAP79/150 are 1) direct interaction of P2Y11 with the scaf-
fold protein and/or 2) association of the receptor with a pool of CaV1.2 within the AKAP79/150 com-
plex. Future studies should examine these exciting alternatives as they may provide further insight
into mechanisms regulating LTCCs and vascular reactivity during diabetic hyperglycemia.
A lingering question is how nucleotides, such as ATP, are released in response to glucose to mod-
ulate arterial myocyte excitability. Although our data do not identify the specific nucleotide, ATP
release is particularly interesting as this nucleotide is an effective vasoactive agent and the endoge-
nous P2Y11 agonist (Communi et al., 1997; Kennedy, 2017; Schuchardt et al., 2012;
von Ku¨gelgen and Harden, 2011). Indeed, ATP can activate P2Y11 with an EC50 that ranges from
1.8 to 17 mM, depending on the readout and the cell type used (Communi et al., 1999; Haas et al.,
2014; Meis et al., 2010; Qi et al., 2001). Moreover, P2Y11 can be activated by ATP/ATP-derived
nucleotides with the following potency order: ATPgS > dATP > ATP>>>ADP, with other nucleotides
such as UTP and UDP having minimal or no influence on receptor activation (Kennedy, 2017;
Schuchardt et al., 2012; von Ku¨gelgen and Harden, 2011). Our recent study suggested that glu-
cose effects on LTCC activity and vascular reactivity require glucose transport into the cell and sub-
sequent metabolism that can generate ATP (Nystoriak et al., 2017). ATP can then be transported
out of the cell through ATP-binding cassettes, vesicular exocytosis, plasma membrane F1F0-ATPase,
connexin hemichannels and pannexin channels to induce activation of P2Y11 (Lohman et al., 2012).
We thus speculate that one of these ATP transporters could form part of the AKAP/P2Y11/AC/PKA/
CaV1.2 nanocomplex to provide another layer of compartmentalization that facilitates PKA-depen-
dent regulation of LTCC function and vascular reactivity in response to elevations in extracellular
glucose.
In summary, our data in human and murine tissue provide evidence of a Gs-coupled purinergic
receptor that fits the profile of P2Y11 or a P2Y11-like receptor, respectively, as a key upstream com-
ponent in the signaling cascade regulating LTCC activity and vascular reactivity during diabetic
hyperglycemia. Data start to define a unique nanomolecular complex likely formed by AKAP/P2Y11/
AC/PKA/CaV1.2. This nanocomplex can organize glucose signaling and help explain the intriguing
consequences of glucose-induced PKA activation on LTCC function and vascular reactivity, which
may have significant pathological implications, and therapeutic potential to treat vascular complica-
tions during diabetic hyperglycemia.
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type (species)
or resource Designation Source or reference Identifiers
Additional
information
Reagent
type (species)
or resource Designation Source or reference Identifiers
Additional
information
Strain
(Mus musculus),
C57BL/6J
wild-type Jackson Laboratories stock # 000664
Strain
(Mus musculus)
S1928A (Lemke et al., 2008)
Cell line
(human
embryonal
kidney)
tsA-201 Sigma-Aldrich 96121229 SV40 transformed
Oligode
oxynucleotide,
sense
P2Y11 SNS ODN Integrated DNA
Technologies
human P2Y11 sequence
(NC_000019.10):
5’-CAACGTCTCGG
GTAAGGAGAA-3’
and 5’-ATGAGGAAGG
AAACGTGGGT-3’
last three bases on the
3’ end were
phosphoro-thioated
Oligode
oxynucleotide, antisense
P2Y11 ANS ODN Integrated DNA
Technologies
human P2Y11 sequence
(NC_000019.10):
5’-CAAGGCCACCCTAACCACTG-3’
and 5’-CTCTCCCTTCCCTGCGTTA-3’
last three bases on
the 3’ end were
phosphoro-thioated
DNA construct human P2Y11 UMR cDNA
Resource Center
www.cDNA.org; clone ID
P2Y1100000
tagged with GFP at C-
terminus
Antibody anti-FP1 (CaV1.2;
custom rabbit)
(Davare et al., 2000) dilutions: 1:100 for
immunoblot and PLA;
10 mg/mL for GSD
Antibody anti-CH3P
(pSer1928,
custom rabbit)
(Davare et al., 2000) 1:50-1:100 dilutions
Antibody anti-b-actin
(mouse monoclonal)
Abcam ab8226
RRID: AB_30637
1:1000 dilution
Antibody anti-a-tubulin
(mouse monoclonal)
Active Motif 39527; clone 5-B-1–2 1:500 dilution
Antibody anti-P2Y11 (rabbit polyclonal) Abcam ab180739 1:100-1:200 dilutions
Antibody anti-P2Y11 (goat polyclonal) Santa Cruz
Biotechnology
sc-69588; clone C-18
RRID: AB_21559
dilutions: 1:100 for
stainings (PLA,
classical) and 10 mg/mL
for GSD
Antibody anti-PKAcat
a, b, g
(mouse
monoclonal)
Santa Cruz
Biotechnology
sc-28315; clone A-2 1:200 dilution
Antibody PKAcat
a, b, g
blocking peptide
Santa Cruz
Biotechnology
sc-28315 P; clone A-2 1:20 dilution
for 1 mg of primary
antibody
Antibody anti-PKAcat a, b, g
(rabbit polyclonal)
Santa Cruz
Biotechnology
sc-28892; clone H-95 dilutions: 1:200 for
PLA and 10 mg/mL for GSD
Antibody Alexa Fluor 488
conjugate of
wheat germ
agglutinin
Life Technologies W7024
Antibody Alexa Fluor
568-conjugated
donkey anti-goat
Molecular Probes A11057
RRID: AB_142581
5 mg/mL dilution
Continued on next page
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Continued
Reagent
type (species)
or resource Designation Source or reference Identifiers
Additional
information
Antibody Alexa Fluor
568-conjugated
donkey anti-mouse
Molecular Probes A10037 5 mg/mL dilution
Antibody Alexa Fluor
568-conjugated
donkey anti-rabbit
Molecular Probes A11011
RRID: AB_143157
2 mg/mL dilution
Antibody Alexa Fluor
647-conjugated
donkey anti-goat
Molecular Probes A21447
RRID: AB_141844
2 mg/mL dilution
Antibody goat anti-rabbit
IgG (H + L)
-horseradish
peroxidase conjugate
Bio-Rad 170–6515
RRID: AB_11125142
1:10000 dilution
Antibody goat anti-mouse
IgG (H + L)-
horseradish
peroxidase conjugate
Bio-Rad 170–6516 1:10000 dilution
Chemical
compound,
drug
sodium
pentobarbital
(Fatal-Plus)
Vortech
Pharma-ceuticals
NDC 0298-9373-68
Chemical
compound,
drug
mannitol Fisher
Scientific
BP686
Chemical
compound,
drug
NF340 Santa Cruz
Biotechnology
sc-361274
Chemical
compound,
drug
NF546 Tocris 3892
Chemical
compound,
drug
apyrase New England
Biolabs
M0398L
Chemical
compound,
drug
nifedipine Sigma-Aldrich N7634
Chemical
compound,
drug
Bay K-8644 Sigma-Aldrich 71145-03-4
Chemical
compound,
drug
forskolin Sigma-Aldrich F6886
Chemical
compound,
drug
amphotericin B Sigma-Aldrich A4888
Chemical
compound,
drug
MRS2578 Santa Cruz
Biotechnology
sc-204103A
Chemical
compound,
drug
MRS2179 Tocris 1454889-37-2
Chemical
compound,
drug
protein kinase
A inhbitor (PKI)
Sigma-Aldrich P9115 fragment
14–22,
myristoylated
trifluoroacetate salt
Continued on next page
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Continued
Reagent
type (species)
or resource Designation Source or reference Identifiers
Additional
information
Chemical
compound,
drug
Rp-Adenosine
3’,5’-cyclic
monophos-
phorothioate
triethylam-monium
salt (rpcAMP)
Sigma-Aldrich A165
Chemical
compound,
drug
Adenosine
5’-[g-thio]
triphosphate
tetralithium
salt (ATPgS)
Sigma-Aldrich A1388
Software,
algorithm
GraphPad Prism GraphPad Prism, RRID: SCR_002798
Software,
algorithm
ImageJ Fiji,
RRID: SCR_002285
Software,
algorithm
pCLAMP10 Molecular
Devices
electrophysiology
Software,
algorithm
LASAF Leica GSD
Software,
algorithm
IonOptix IonOptix arterial diameter
recordings
Software,
algorithm
Metaflor Molecular
Devices
FRET
Animals
Male wild type C57BL/6J (wt) or knockin mice in which Ser1928 of CaV1.2 was mutated to Ala
(S1928A) (Lemke et al., 2008) of 5 to 8 weeks of age were euthanized with a lethal dose of sodium
pentobarbital (250 mg/kg; intraperitoneally), as approved by the University of California, Davis Ani-
mal Care and Use Committee (protocol #: 20321).
Human tissue
Excised adipose arteries from human patients undergoing surgical sleeve gastrectomy were used for
this study (Supplementary file 3). Samples were obtained after Institutional Review Board (IRB)
approval from the University of Nevada Reno School of Medicine (IRB ID: 2013–019) and in accor-
dance with the guidelines of the Declaration of Helsinki. The need for informed consent was waived
by IRBs at the University of Nevada Reno School of Medicine (IRB ID: 2013–019) and the University
of California Davis (IRB ID: 597267–1) because the tissue is considered ‘waste’, has no codification
that could be used to identify patients and was determined not to be human subject research in
accordance with United States of America federal regulations, as defined by 45 CFR 46.102(f). This
precludes the acquisition of detailed clinical profiles other than sex, age and whether the patient
is nondiabetic or diabetic. Only samples from nondiabetic patients were used. No exclusions were
made due to medication history, sex or presence of comorbidities. Collected tissue was placed in
cold phosphate-buffered saline (PBS) solution containing (in mM): 138 NaCl, 3 KCl, 10 Na2HPO4, 2
NaH2PO4, 5 D-glucose, 0.1 CaCl2, and 0.1 MgSO4, pH 7.4 with NaOH until used.
Arterial myocyte isolation
Mouse cerebral arteries were dissected in ice-cold dissection buffer containing (in mM): 140 NaCl, 5
KCl, 2 MgCl2, 10 D-glucose, 10 HEPES, pH 7.4, with NaOH. Arteries were digested in dissection
buffer containing papain (1 mg/mL) and dithiothreitol (1 mg/mL) at 37˚ C for 7 min, followed by incu-
bation in dissection buffer containing collagenase type F (0.7 mg/mL) and collagenase type H (0.3
mg/mL) at 37˚ C for 7 min. Arteries were washed in ice-cold dissection buffer and gently triturated
with glass pipettes to disperse the cells, which were kept in ice-cold dissection buffer until use.
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Single human arterial myocytes (Supplementary file 3) were isolated as previously described
(Nieves-Cintro´n et al., 2017; Nystoriak et al., 2017). Briefly, small diameter adipose arteries from
human samples were enzymatically digested in dissection solution supplemented with papain (26 U/
mL) and dithiothreitol (1 mg/mL) at 37˚ C for 15 min, followed by incubation in dissection solution
containing collagenase type H (1.95 U/mL), elastase (0.5 mg/mL), and trypsin inhibitor (1 mg/mL) at
37˚ C for 10 min. Cells were then washed three times in ice-cold dissection buffer, triturated with
glass pipettes to disperse the individual cells, and maintained in ice-cold dissection buffer until use.
For unpassaged, cultured human and mouse arterial myocytes, human adipose arteries and
mouse aortas were dissected out and placed in ice-cold Dulbecco’s Modified Eagle Medium
(DMEM; Gibco – Life Technologies, Grand Island, NY) containing 1X glutamate, 1X pyruvate, 1X
penicillin/streptavidin and fungizone (0.25 g/mL). Artery segments were subsequently transferred
and incubated in a DMEM solution containing 2.2 mg/mL of collagenase Type 2 (Worthington) at
37˚ C for 15 min to remove the adventitia. To disperse and culture unpassaged arterial myocytes,
the tissue was cut into 2–5 mm segments and incubated at 37˚ C with constant shaking in a buffer
containing (in mM): 134 NaCl, 6 KCl, CaCl2, 10 HEPES, and 7 D-glucose supplemented with 2.2 mg/
mL collagenase Type 2 (Worthington). The digestion was stopped by adding an equal volume of
DMEM containing 5% fetal bovine serum. Digested tissue was then centrifuged for 5 min at 14,000
rpm. The supernatant was removed and the pellet containing the digested tissue was resuspended
in DMEM containing 1X glutamate, 1X pyruvate, 5% serum and 5 mM D-glucose, resulting in disper-
sion of individual arterial myocytes. Cells were then seeded on glass coverslips coated with laminin
and kept in an incubator at 37˚ C with 5% CO2 for 2–3 days before adenoviral transduction or lysis
for immunoblotting (see section below).
Arterial diameter measurements
Freshly isolated posterior mouse cerebral arteries were cannulated on glass micropipettes mounted
in a 5 mL myograph chamber (University of Vermont Instrumentation and Model Facility), as
described previously (Nieves-Cintro´n et al., 2017; Nystoriak et al., 2014; Nystoriak et al., 2017).
Arteries were allowed to equilibrate at an intravascular pressure of 20 mmHg, while being continu-
ously superfused (37˚ C, 30 min, 3–5 mL/min) with physiological saline solution composed of (in
mM): 119 NaCl, 4.7 KCl, 2 CaCl2, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 0.023 EDTA, and 10 D-glu-
cose aerated with 5% CO2/95% O2. Bath pH was closely monitored and maintained at 7.35 to 7.4.
After equilibration, intravascular pressure was increased to 60 mmHg and arteries allowed to
develop stable myogenic tone. Arteries not exhibiting stable tone after ~1 hr were discarded. To
assess the response of arterial diameter to hyperglycemia, D-glucose was increased from 10 mM to
20 mM in the perfusion solution. Arterial tone data are presented as a percent decrease in diameter
relative to the maximum passive diameter at 60 mmHg obtained using Ca2+-free saline solution con-
taining nifedipine (1 mM) at the end of the experiment.
Electrophysiology
All experiments were performed at room temperature (22–25˚ C). Both whole-cell and single-channel
data were acquired using an Axopatch 200B amplifier and Digidata 1440 digitizer (Molecular Devi-
ces). Recording electrodes were pulled from borosilicate capillary glass using a micropipette puller
(model P-97, Sutter Instruments) and subsequently polished to achieve resistances that ranged from
3.5 to 6.5 MW. L-type Ca2+ channel currents were assessed in freshly dissociated arterial myocytes
using the perforated whole-cell mode of the patch-clamp technique with Ba2+ as a charge carrier
(IBa) after myocytes were allowed to attach (10 min) to a glass coverslip in a recording chamber.
Borosilicate glass pipettes were filled with a solution containing (in mM): 120 CsCl, 20 tetraethylam-
monium chloride (TEA-Cl), 1 EGTA, and 20 HEPES with amphotericin B (250 mg/mL; pH adjusted to
7.2 with CsOH). The bath solution consisted of (in mM): 115 NaCl, 10 TEA-Cl, 0.5 MgCl2, 10 D-glu-
cose, 5 CsCl, 20 BaCl2, and 20 HEPES, pH adjusted to 7.4 with CsOH. IBa were elicited by 200 ms
depolarizing pulses from a holding potential of  70 mV to +10 mV. IBa were first recorded in the
presence of 10 mM D-glucose under static flow conditions. This solution was then exchanged for a
solution containing either 20 mM D-glucose, 20 mM mannitol or NF546 at a rate of 2.1 mL/min.
Flow was stopped after 3 min, and IBa were recorded again under static flow conditions at least 5
min after the indicated treatment was initiated. In some experiments, arterial myocytes were
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pretreated for 10–15 min with indicated inhibitors prior to IBa recordings. For experiments compar-
ing IBa before and after elevated glucose under continuous flow and static bath conditions, cells
were patched in a bath solution containing 10 mM D-glucose at a perfusion rate of 2.1 mL/min. After
establishment of a stable gigaseal for at least 5 min, IBa were recorded in the presence of 10 mM
D-glucose under continuous flow. Those cells that showed robust IBa in 10 mM D-glucose were then
perfused with a bath solution containing 20 mM D-glucose under continuous flow for at least 5 min
before recording of IBa again. Subsequently, IBa were recorded one more time on the same cell, 5
min after stopping the bath perfusion (e.g. static bath conditions). Currents were sampled at 10 kHz
and low pass-filtered at 5 kHz. The CaV1.2 blocker nifedipine (1 mM) was applied at the end of each
experiment to determine the nifedipine-sensitive component. The I-V relationship of nifedipine-sen-
sitive IBa was determined by 200 ms depolarizing steps from  70 mV to voltages ranging from  60
to +60 mV in increments of +10 mV. The I-V relationship for averaged data sets was fit with a peak
Gaussian function: I(V)=Imax x exp( 0.5((V – Vmax)/b)
2), where Imax is peak I, Vmax is V at Imax, and b is
the slope of the distribution, as described previously (Nystoriak et al., 2017). A voltage error of 10
mV attributable to the liquid junction potential of the recording solutions was corrected offline.
The cell-attached configuration of the patch-clamp technique was used to examine single-channel
Ca2+ currents in arterial myocytes using Ca2+ as the charge carrier, as previously described
(Cheng et al., 2011; Dixon et al., 2015; Dixon et al., 2012; Navedo et al., 2010a;
Nystoriak et al., 2017). Resting membrane potential was fixed to ~0 mV using a high K+ bath solu-
tion (Hess et al., 1986; Zampini et al., 2006) composed of (in mM): 145 KCl, 10 NaCl, and 10
HEPES, pH adjusted to 7.4 with NaOH. Pipette solution was composed of (in mM): 120 TEA-Cl, 110
CaCl2, and 10 HEPES with BayK-8644 (500 nM), which promotes longer open times of the channel
thereby increasing the probability of sweeps with channel activity. Single L-type Ca2+ currents were
elicited by a 2 s depolarizing step from a holding of  70 mV to  30 mV. Single-channel currents
were sampled at 10 kHz and low pass filtered at 2 kHz, followed by a Gaussian filter (500 Hz) during
analysis. Capacitive currents were compensated by subtraction of blank sweeps. When nifedipine
was included in the patch pipette, CaV1.2 activity was negligible. Single-channel openings and nPo
were analyzed using the single-channel event half-amplitude detection algorithm from pCLAMP 10.
Immunoprecipitation and immunoblotting
Human adipose arteries, mouse cerebral and mesenteric arteries, and mouse arterial myoyctes were
homogenized in a RIPA lysis buffer solution composed of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5
mM EGTA, 10 mM EDTA, 1% nonyl phenoxypolyethoxylethanol-40 (NP-40), 10% glycerol, 0.05%
sodium dodecyl sulfate (SDS), 0.4% deoxycholic acid (DOC) with protease inhibitors (1 mg/ml pepsta-
tin A, 10 mg/ml leupeptin, 20 mg/mL aprotinin, and 200 nM phenylmethylsulfonyl fluoride) and phos-
phatase inhibitors (2 mM microcystin LR, 1 mM p-nitrophenyl phosphate, 50 mM Na-pyrophosphate,
and 50 mM NaF), then sonicated for 5 min at 4˚ C and cleared by centrifugation (15,000 X g) for 20
min at 4˚ C. For Ser1928 phosphorylation experiments, the soluble fraction was incubated on a head-
over-head tilter with protein A-Sepharose beads and a purified custom antibody against CaV1.2 (5
mg of FP1; see Davare et al., 2000) or nonspecific rabbit immunoglobulin G (IgG) control for 4 hr at
4˚ C. Beads were washed three times with washing buffer containing (in mM): 150 NaCl, 10 EDTA,
10 EGTA, 10 Tris-HCl (pH 7.4), 0.1% Triton X-100, pH 7.4. Samples were extracted in Laemmli Sam-
ple Buffer (Bio-Rad) for 5 min at 95˚ C for immunoprecipitation (Ser1928 phosphorylation) experi-
ments and 15 min at 80˚ C for other immunoblot experiments. Proteins were separated by SDS-
polyacrylamide gel electrophoresis at 75–100 V for 1.5 hr in a stacking gel polymerized from 3%
acrylamide and a resolving phase polymerized from 7.5% (Ser1928 phosphorylation) or 10% acrylam-
ide. Proteins were then transferred to a polyvinylidene difluoride membrane at 50 V for 600 min at
4˚ C. All membranes, except for P2Y11 blots (10% Odyssey blocking buffer; LI-COR Biosciences),
were blocked in 5% nonfat dried milk in tris-buffered saline with 0.05% Tween 20 (TBS-T) for 1 hr at
room temperature before primary antibody incubation for 2–3 hr at room temperature. Antibodies
and dilutions were as follows: rabbit anti-CH3P (pSer1928; 1:50-1:100),(Davare et al., 2000) rabbit
anti-FP1 (CaV1.2; 1:100) (Davare et al., 2000), rabbit anti-P2Y11 (Abcam, 1:100-1:200); mouse anti-b-
actin (Abcam, 1:1000), and anti a-tubulin (Active Motif, 1:500). Except for the P2Y11 antibody, which
was diluted in 1% bovine serum albumin, all antibodies were diluted in 5% nonfat dried milk in TBS-
T. After washing, membranes were then incubated 1 hr at room temperature with horseradish perox-
idase-labeled goat anti-rabbit (Bio-Rad; 1:10,000) or goat-anti-mouse antibodies (Bio-Rad; 1:10,000)
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diluted in 5% nonfat dried milk in TBS-T or 5% Odyssey in TBS-T (P2Y11 only) and developed on
autoradiography film using chemiluminescence (Classico [Millipore] and Femto [Thermo Fisher Scien-
tific]). For Ser1928 phosphorylation and P2Y11 knock down experiments, total CaV1.2 and b-actin,
respectively, were used for normalization (density expressed as percentage of total CaV1.2/b-actin
and these ratios were normalized to the ratio of the control band to get the relative density of
pSer1928/CaV1.2 or P2Y11/b-actin for all treatments). For Ser
1928 phosphorylation quantification in
Figure 1—figure supplement 1E, triplicates were run in parallel and all values were normalized to
the ratio of the loading control band (e.g. a-tubulin obtained from the same samples) to get the
pSer1928/a-tubulin ratio for all treatments. The pSer1928/a-tubulin ratios were then normalized to the
first control band ratio to obtain the relative density of pSer1928/a-tubulin. Densitometry analysis for
bands was performed with ImageJ software (National Institutes of Health) as follow. Developed films
were scanned to tiff files, uploaded to ImageJ and color inverted. Immunoreactive bands were out-
lined and light intensity per area was measured. Doublet bands were outlined and measured as one
signal. Intensity of equal area above and below each immunoreactive band was measured to average
and then subtract the background signal. Importantly, films were exposed for increasing time peri-
ods to ensure signals were in the linear range as described in Davare and Hell (2003) and
Hall et al. (2006). b-actin and a-tubulin were used as a loading control in some experiments.
Organ culture
Freshly isolated arteries for acute Ser1928 phosphorylation experiments were incubated for 5 min at
room temperature in a physiological saline solution composed of (in mM): 119 NaCl, 4.7 KCl, 2
CaCl2, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 0.023 EDTA, and 10 (5 for humans) D-glucose aerated
with 5% CO2/95% O2 to reach a pH of 7.35–7.4. Arteries were then incubated for 10 min at room
temperature in a similar physiological solution containing the specified treatment. Following incuba-
tion, arteries were immediately placed in RIPA lysis buffer with protease and phosphatase inhibitors
(as described in immunoblotting section). For chronic exposure experiments, arteries were placed in
DMEM/F-12 (Gibco-Life Technologies, Grand Island, NY) supplemented with L-glutamine (2 mM)
containing 10 mM, 20 mM D-glucose or 20 mM mannitol in the absence or presence of 10 mM
NF340 and incubated for 48 hr at 37˚ C. After incubation, arteries were quickly washed in PBS and
then placed in RIPA lysis buffer with protease and phosphatase inhibitors for immunoblotting.
Immunofluorescence
Immunofluorescent labeling of freshly dissociated arterial myocytes was performed as described pre-
viously (Navedo et al., 2008), using a goat-anti P2Y11 (Santa Cruz Biotechnology, clone C-18; 1:100)
or a mouse-anti PKAcat a, b, g (Santa Cruz Biotechnology, clone A-2, 1:200) antibodies in PBS sup-
plemented with 0.1% BSA. Alexa Fluor 488 conjugated wheat germ agglutinin (WGA; Life Technolo-
gies) was used to stain for the plasma membrane. The secondary antibodies were Alexa Fluor 568-
conjugated donkey anti-goat and donkey anti-mouse (5 mg/mL; Molecular Probes). In control experi-
ments, the PKAcat antibody was preabsorbed with a PKAcat blocking peptide (Santa Cruz Biotechnol-
ogy, A-2; 1:20 for 1 mg of primary antibody). Cells were imaged (512  512 pixel images) using an
Olympus FV1000 confocal microscope paired with an Olympus 60x oil immersion lens (NA = 1.4)
and a zoom of 3.0 (pixel size = 0.1 mm). P2Y11-associated fluorescence was not detected in negative
control experiments in which the primary antibody was substituted for PBS or boiled to test for anti-
body specificity. Cells for each group were imaged with the same laser power, gain settings, and
pinhole.
Proximity ligation assay
A Duolink In Situ PLA kit (Sigma) (Fredriksson et al., 2002) was used to detect complexes consisting
of P2Y11 and CaV1.2 and P2Y11 and PKAcat in freshly isolated arterial myocytes as previously
described (Nieves-Cintro´n et al., 2017; Nystoriak et al., 2017). Briefly, cells were plated on glass
coverslips and allowed to adhere (1 hr, room temperature) prior to fixing with 4% paraformaldehyde
(20 min), quenching in 100 mM glycine (15 min), and washing in PBS (2  3 min). Cells were permea-
bilized with 0.1% Triton X-100 (20 min) and then blocked (1 hr, 37˚ C) in 50% Odyssey blocking solu-
tion (LI-COR Bioscience). Cells were incubated overnight at 4˚ C with a specific combination of two
primary antibodies in 0.1% Odyssey +0.05% Triton X-100 PBS solution: goat anti-P2Y11 (Santa Cruz
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Biotechnology, clone C-18; 1:100), custom rabbit anti-FP1 (CaV1.2, 1:100) (Davare et al., 2000) and
rabbit anti-PKAcat a, b, g (Santa Cruz Biotechnology, clone H-95, 1:200). Cells were incubated with
only one primary antibody as negative controls. After primary antibody incubation, cells were
washed with Duolink buffer A (2  5 min). Oligonucleotide-conjugated secondary antibodies (PLA
probes: anti-goat MINUS and anti-rabbit PLUS) were used to detect P2Y11 and CaV1.2 and P2Y11
and PKAcat (1 hr, 37˚ C). Following incubation with probes, cells were washed with Duolink buffer A
(2  5 min) and a ligation solution composed of two distinct oligonucleotides, complementary to the
probes, and ligase was added (30 min, 37˚ C) to allow hybridization with the probes and formation
of a closed DNA circle at sites of dual labeling, which serves as a template for a rolling circle amplifi-
cation reaction (100 min, 37˚ C). After the amplification step, cells were washed with Duolink buffer
B (2  10 min) and 1% buffer B (1  1 min). Coverslips were allowed to dry and subsequently
mounted on a microscope slide with Duolink mounting medium. The fluorescence signal was
detected using an Olympus FV1000 confocal microscope coupled with a 60x oil immersion lens (NA,
1.4). Images were collected at different optical planes (z-axis step = 0.5 mm). The stack of images for
each sample was combined into a single-intensity projection image that was subsequently used for
analysis of number of puncta/mm2 per cell.
Immunolabeling and Ground State Depletion (GSD) microscopy
Isolated arterial myocytes were allowed to adhere to a coverslip (1 hr) before fixing with 3% parafor-
maldehyde +0.1% glutaraldehyde solution in PBS (10 min) followed by washes with PBS (3  15
min). Cells were then incubated for 5 min with 0.1% sodium borohydride in H2O, followed by 3  5
min washes with PBS and incubated in permeabilization/blocking solution consistent of 0.05% Triton
X-100% and 20% SEA BLOCK (Thermo Scientific) for 1 hr at room temperature. Cells were exposed
overnight to primary antibodies [goat anti-P2Y11 (Santa Cruz Biotechnology, clone C-18), custom
rabbit anti-CaV1.2 (FP1 (Davare et al., 2000)) or rabbit anti-PKAcat a, b, g (Santa Cruz Biotechnol-
ogy, clone H-95)] diluted in blocking buffer to a concentration of 10 mg/mL. Cells were briefly
washed 3x with PBS, followed by additional longer washes (3x for 15 min). For secondary antibodies,
donkey Alexa Fluor 647-conjugated antibody recognizing goat IgG (2 mg/mL; Molecular Probes) and
donkey Alexa Fluor 568-conjugated antibody recognizing rabbit IgG (2 mg/mL; Molecular Probes)
diluted in blocking buffer were added for 1 hr at room temperature. Secondary Ab was washed 3x
with PBS, followed by longer washes (3x for 15 min). Specificity of secondary antibodies was tested
in control experiments in which primary antibodies were omitted from the preparation (no 1˚ anti-
body controls). For imaging, coverslips were mounted on microscope slides with a round cavity con-
taining MEA-GLOX imaging buffer (NeoLab Migge Laborbedarf-Vertriebs GmbH, Germany) and
sealed with Twinsil (Picodent, Germany). The imaging buffer was composed of 10 mM MEA (cyste-
amine), 0.56 mg/mL glucose oxidase, 34 mg/mL catalase, and buffer containing 10% w/v glucose, 10
mM NaCl, and 50 mM Tris-HCl, pH 8.
Super-resolution images of arterial myocytes were obtained using a super resolution ground state
depletion system (SR-GSD, Leica) dependent on stochastic single-molecule localization, equipped
with high-power lasers (532 nm, 2.1 kW/ cm2; 642 nm, 2.1 kW/ cm2) and an additional 30 mW, 405
nm laser. A 160x HCX Plan-Apochromat (NA 1.47) oil immersion lens and an electron-multiplying
charge-coupled device (EMCCD) camera (iXon3 897; Andor Technology) were used to acquire
images (Dixon et al., 2015). The camera was running in frame-transfer mode at a frame rate of 100
Hz (10 ms exposure time). Fluorescence was detected through Leica high-power TIRF filter cubes
(532 HP-T, 642 HP-T) with emission band-pass filters of 550–650 nm and 660–760 nm. Reconstruc-
tion of P2Y11, CaV1.2, and PKA distribution from 30,000 images used the coordinates of centroids
obtained by fitting single-molecule fluorescence signals with a 2D Gaussian function using a LASAF
software (Leica). The localization accuracy of the system is limited by the statistical noise of photon
counting; the precision of localization is proportional to DLR/HN, where DLR is the diffraction-lim-
ited resolution of a fluorophore and N is the average number of detected photons per switching
event, assuming the point-spread functions are Gaussian (Dempsey et al., 2011; Fo¨lling et al.,
2008). The full width at half maximum for single-molecule signals was ~20 nm as recently calculated
by our group (Tajada et al., 2017). Localizations produced from less than 800 photons were filtered
out of the reconstruction. All pixels with intensity above a user-defined threshold were binarized,
evaluated and segmented into individual objects and included as clusters in our analysis. Cluster size
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and density were determined using the Analyze Particle option in the ImageJ software (National
Institute of Health). The JACoP plug-in in the ImageJ software was used to unbiasedly and automati-
cally determine the shortest intermolecular distances for P2Y11 and CaV1.2 as well as P2Y11 and PKA-
cat following the protocol described by Bolte and Cordelie`res (2006). Intermolecular distance
histograms were generated from the JACoP plug-in output data and fitted with a sum of two Gauss-
ian functions of the following equation: Y =Y0 + (A1 / (w1 x H(p/2))) x exp( 2 x ((X - XC1)/w1)
2) + (A2 /
(w2 x H(p/2))) x exp( 2 x ((X - XC2)/w2)
2), where Y0 is the Y offset, A1 and A2 are the areas of the dis-
tribution of distances, XC1 and XC2 are the x values of distance at the center of the distribution, and
w1 and w2 are the widths of each distribution in nanometers. To calculate the percentage of com-
plete P2Y11 overlap, we first quantified the number of clusters/objects in the thresholded, binarized
localization maps for P2Y11 and CaV1.2 as well as P2Y11 and PKAcat using the Analyze Particle tool in
ImageJ. The binarized localization maps of P2Y11 were then multiplied by those corresponding to
the paired CaV1.2 or PKAcat localization maps. The number of objects obtained from this operation
were then divided by the number of clusters/objects present in the original binarized localization
maps for P2Y11. This method only detects objects that are 100% overlapping with each other in two
independent images (e.g localization maps for P2Y11 and CaV1.2). Random simulation of image pairs
for P2Y11 and CaV1.2 or P2Y11 and PKAcat were generated based on the original super-resolution
localization maps for each pair of proteins using the Coste’s randomization algorithm included in the
JACoP plug-in in ImageJ (Bolte and Cordelie`res, 2006) from six different cells per condition.
Parameters for the Coste’s randomization algorithm were selected to generate simulated images
with relative similar cluster size and density to those observed in the original super-resolution locali-
zation maps for each protein. Each randomized image was generated after undergoing 1000 ran-
domization rounds. Randomized images were binarized prior to analysis and the percentage of
complete P2Y11 overlap from the randomized image pairs was calculated as described above.
Cell culture, transfection of tsA-201 cells, and reverse permeabilization
tsA-201 were obtained from Sigma-Aldrich (cat#: ECACC 96121229). These cells are included in the
European Collection of Authenticated Cell Cultures. tsA-201 cells were cultured in DMEM supple-
mented with 1X pyruvate, 1X glutamax, 8% fetal bovine serum (FBS) and 5 mM glucose (without
phenol red) at 37˚ C in a 5% CO2 incubator. Cells were transfected at 60–70% confluence with
human P2Y11 tagged with GFP at C-terminus (UMR cDNA Resource Center - www.cDNA.org; clone
ID P2Y1100000) with JetPRIME transfection reagent (Polyplus transfection SA, NY) for approximately
36 hr. P2Y11 sense and antisense oligodeoxynucleotides (ODNs; 2 mM; Integrated DNA Technolo-
gies) were transfected in tsA-201 cells 24 hr after initial transfection with P2Y11-GFP. The cells were
gently washed with 1X PBS and then removed with a cell scrapper using a RIPA lysis buffer solution
composed of 50 mM Tris base, 150 mM NaCl, 5 mM EGTA, 10 mM EDTA, 1% nonyl phenoxypolye-
thoxylethanol-40 (NP-40), 10% glycerol, 0.05% sodium dodecyl sulfate (SDS), 0.4% deoxycholic acid
(DOC) with protease inhibitors (1 mg/mL pepstatin A, 10 mg/mL leupeptin, and 20 mg/mL aprotinin).
Antisense and sense ODNs for P2Y11 were designed and checked for specificity using Prime BLAST
against the human P2Y11 sequence (NC_000019.10). The sequences used for the antisense ODNs
were as follows: 5’-CAAGGCCACCCTAACCACTG-3’ and 5’-CTCTCCCTTCCCTGCGTTA-3’. The
sequences for sense ODNs were 5’-CAACGTCTCGGGTAAGGAGAA-3’ and 5’-ATGAGGAAG-
GAAACGTGGGT-3’. For all ODNs, the last three bases on the 3’ end were phosphorothioated to
reduce degradation by cellular nucleases. ODNs were dissolved in nuclease-free water to a 1 mM
concentration.
Human adipose arteries were permeabilized in a solution containing (in mM): 120 KCl, 2 MgCl2,
10 EGTA, 5 Na2ATP, 20 TES (2-[(2-Hydroxy-1, 1-bis(hydroxymethyl)ethyl)amino] ethanesulfonic acid,
N-[Tris(hydroxymethyl)methyl] 2-aminoethanesufonic acid), pH adjusted to 6.8 with NaOH. Arteries
were first incubated in permeabilization solution for 20 min at 4˚C, followed by a 4 hr incubation at
4˚C in a solution supplemented with ODNs (2 mM). Arteries were placed in an ODN-containing solu-
tion with elevated MgCl2 (10 mM) for 1 hr at room temperature. Permeabilization was reversed by
incubating arteries for 30 min at room temperature in MOPS physiological solution composed of (in
mM): 140 NaCl, 5 KCl, 10 MgCl2, 5 D-glucose, and 2 MOPS, pH adjusted to 7.1 with NaOH. Arteries
were incubated in a MOPS solution containing 0.01, 0.1, and 1.8 mM CaCl2 in 15 min intervals,
increasing Ca2+ gradually. After completing reverse permeabilization, arteries were cultured in
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D-MEM/F-12 culture media supplemented with L-glutamine (2 mM) for 2.5 days at 37˚C. Arteries
were then lysed and used for Western blot (see Immunoblotting section).
Adenovirus infection of unpassaged arterial myocytes and Fluorescence
Resonance Energy Transfer (FRET)
Laminin (Life Technologies, Grand Island, NY) diluted 100x in sterile-filtered PBS (137 mM NaCl, 2.7
mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH = 7.4) was used to coat #0 glass coverslips (Karl
Hecht, Sondheim, Germany). After adding diluted laminin (100 mL per coverslip), coverslips were
placed in a 37˚ C incubator with 5% CO2 for a minimum of 2 hr, then moved to 24-well plate wells
(Falcon, Tewksbury, MA), and washed 3x with sterile-filtered PBS. Freshly dissociated human adipose
arterial myocytes and mouse aortic cells were plated on the laminin-coated coverslips with 500 mL of
serum-containing media for 48 hr in a 37˚ C incubator with 5% CO2. Media was then replaced with
500 mL of serum-free media-containing virus coding for the membrane-targeted Epac1-camps-based
FRET sensor (ICUE3-PM) (Allen et al., 2006; Liu et al., 2011) and placed at 37˚ C with 5% CO2 for
another 36 hr. Viruses were produced using the AdEasy system (Qbiogene, Carlsbad, CA)
(Luo et al., 2007). After infection, media was changed to serum-free media without virus. Glass cov-
erslips were transferred to glass bottom culture dishes (MatTek, Ashland, MA) containing 3 mL PBS
at room temperature.
A Zeiss AXIO Observer A1 inverted fluorescence microscope (San Diego, CA) equipped with a
Hamamatsu Orca-Flash 4.0 digital camera (Bridgewater, NJ) and controlled by Metaflor software
(Molecular Devices, Sunnyvale, CA) acquired phase contrast, CFP480, and FRET images. Phase con-
trast and CFP480 images were collected with 20x and 40x oil immersion objective lenses, while
FRET images were collected using only the 40x oil immersion objective lens. Images for FRET analy-
sis were recorded by exciting the donor fluorophore at 430–455 nm and measuring emission fluores-
cence with two filters (475DF40 for cyan and 535DF25 for yellow). Images were subjected to
background subtraction and acquired every 30 s with exposure time of 200 ms for each channel. The
donor/acceptor FRET ratio was calculated and normalized to the ratio value of baseline. CFP480
images were acquired by exciting the donor fluorophore at 430–455 nm and measuring emission
fluorescence with the 475DF40 filter for 25 ms. Averages of normalized curves and maximal
response to stimulation were graphed based on FRET ratio changes. Binding of cAMP to ICUE3-PM
led to decreases in the YFP/CFP ratio, indicating increases in cAMP levels.
Chemicals and statistics
All chemical reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Data were
analyzed using GraphPad Prism software and expressed as mean ±SEM. Data were assessed for
potential outliers using the GraphPad Prism Outlier Test and for normality of distribution using
appropriate tests. Statistical significance was then determined using suitable paired or unpaired Stu-
dent’s t-test, nonparametric tests or One-way analysis of variance (ANOVA) for multiple comparisons
with proper post hoc test. p<0.05 was considered statistically significant (denoted by * in figures).
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